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Summary 
Introduction 
Description of technology 
In the single-step scaffold-based treatment of cartilage defects, a matrix is im-
planted in the area of the damaged cartilage. The used matrix acts as a tem-
porary structure to allow the cells to be seeded and establish a 3-dimensional 
structure. The matrix decomposes over time. 
In this report we analysed whether the single-step scaffold-based cartilage re-
pair in combination with microfracturing is more effective and safe in com-
parison to microfracturing alone or as effective but safer in comparison to two-
step cartilage repair procedures (autologous chondrocyte implantation or ma-
trix-induced autologous chondrocyte implantation; (M)ACI). 
Health problem 
This systematic review focuses on the treatment of chondral and osteochondral 
lesions in the knee. 
Articular (chondral) cartilage is a thin layer of connective tissue. It provides 
a smooth surface for articulation and facilitates the transmission of forces to 
the underlying subchondral bone.  
A damage of the cartilage can occur due to traumatic events or degeneration 
of the joint or due to osteochondritis dissecans (OCD). The damage can also 
affect the underlying bone (i.e. osteochondral lesion). 
 
Methods 
Answering the research questions regarding efficacy and safety-related out-
comes was based on a systematic literature search from different databases 
and an additional hand search. The study selection, data extraction and assess-
ing the methodological quality of the studies was performed by two review 
authors, independently from each other. 
Domain effectiveness 
The following efficacy-related outcomes were used as evidence to derive a re-
commendation: mobility/joint functionality, quality of life, pain and necessity 
of total joint replacement. 
Domain safety 
The following safety-related outcomes were used as evidence to derive a rec-
ommendation: procedure-related complications, device-related complications 
and re-operations rate. 
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Results 
Available evidence 
We could not identify any controlled trials comparing the single-step scaffold-
assisted treatment of (osteo)chondral defects in the knee with (M)ACI.  
The only studies that met our inclusion criteria are two randomised controlled 
trials (RCTs) and one non-randomised controlled trail with 136 patients of 
the single-step scaffold-assisted chondral repair in the knee joint (scaffold-
groups) in combination with microfracturing (MFx), compared to MFx alone 
(MFx-groups). 
Clinical effectiveness 
The scores measuring the mobility or joint functionality and pain (reported 
in all three controlled trials) plus quality of life (measured in only one study) 
improved in the groups that received the single-step scaffold-assisted treat-
ment (+ MFx) as well as in the groups that received MFx alone in a compa-
rable extent. In all studies, the differences of the improvements between the 
study groups were statistically not significant. 
In one study it was stated that one patient who received a (glued) scaffold, 
the knee joint had to be replaced. 
Safety 
Procedure-related adverse events occurred in 0-93% of the patients in the 
scaffold-groups and in 0-77% of the patients in the control groups. Device-
related adverse events occurred in 0 to 22% of the patients. 
In none of the identified studies it was stated, if any re-operations were nec-
essary.  
Upcoming evidence 
Currently, there are four registered ongoing randomised controlled trials of 
the single-step scaffold-based cartilage repair. 
Reimbursement 
At this point in time, the single-step scaffold-based repair of cartilage defects 
or osteochondritis dissecans (OCD) or (osteo)chondral lesions in the knee 
joint is not reimbursed by the Austrian health care system. 
 
Discussion 
Overall, the strength of evidence for efficacy and safety is low. Exceptions are 
some individual outcomes, like joint functionality and pain, for which the 
strength of evidence was rated as “moderate”. 
Considering the findings of the included studies regarding clinical effective-
ness, it seems that the single-step scaffold-assisted cartilage repair in combi-
nation with MFx leads to similar short to medium-term (up to five years fol-
low-up) results, compared to MFx alone. 
A major issue of the identified trials are the low patient numbers and rela-
tively short follow-ups of one year or less. Only one of the studies had a fol-
low-up of at least five years. Therefore, reliable data of long-term efficacy 
and safety-related outcomes are missing. 
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For assessing the clinical effectiveness and safety of the single-step matrix-
assisted cartilage repair in the knee joint (combined with microfracturing) 
compared to (M)ACI, we could not identify any studies that met our inclu-
sion criteria. 
 
Conclusion 
The current evidence is not sufficient to conclude that the single-step matrix-
assisted cartilage repair (combined with microfracturing) is more effective and 
safer than microfracturing or as effective, but safer than (matrix-assisted) au-
tologous chondrocyte implantation. 
New study results, especially from studies with larger patient numbers and 
longer follow-up (e.g. ten years), will potentially influence the effect estimate 
considerably. 
A re-evaluation is recommended not before 2018, since the technique seems 
to be promising and there are still ongoing studies. At the moment, it seems 
too early to include the single-step scaffold-assisted cartilage repair of the 
knee in the catalogue of benefits. 
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Zusammenfassung 
Einleitung 
Beschreibung der Technologie 
Es gibt verschiedene Varianten für einen einzeitigen matrix-assistierten Knor-
pelersatz. In dem vorliegenden Bericht liegt der Fokus auf dem Verfahren, 
bei dem die Matrix in Kombination mit der Mikrofrakturierung verwendet 
wird. 
Die Mikrofrakturierung ist eine Knochenmarkstimulationstechnik, bei der 
der subchondrale Knochen perforiert wird. Das austretende Knochenmark 
enthält Stammzellen und Wachstumsfaktoren, die zur Chondrogenese beitra-
gen. 
Beim einzeitigen Knorpelersatz wird eine Matrix in den Bereich des Knor-
peldefekts eingebracht, um den Blutpfropf, der durch die Mikrofrakturierung 
entsteht, abzudecken. Diese Technik wird auch als Autologe Matrixinduzier-
te Chondrogenese (AMIC) bezeichnet. Die Matrix soll als Unterstützung für 
die Zellansiedlung dienen.  
Insgesamt konnten acht verschiedene Produkte von acht verschiedenen  
Herstellern identifiziert werden, die alle ein CE-Zertifikat haben: 
 BST-CarGel® (Primal Enterprises Limited, Canada  
 CaReS®-1S (Arthro Kinetics AG, Germany), 
 Chondro-Gide® (Geistlich Pharma, Switzerland), 
 Chondrotissue® (BioTissue Technologies GmbH, Switzerland), 
 GelrinC® (Regentis Biomaterials Ltd., Israel), 
 Hyalofast® (Anika Therapeutics, Inc., USA), 
 MaioregenTM (Fin-Ceramica Faenza S.p.A., Italy), 
 MeRG® (Bioteck S.p.A., Italy). 
Für kleinere Läsionen gilt die Mikrofraktuierung als chirurgische Interven-
tionen der Wahl, während für größere Läsionen die autologe Chondrozyten-
implantation (ACI), die ebenfalls matrix-assistiert sein kann (MACI), ver-
wendet werden kann. Daher wurden sowohl die Mirkofrakturieung als auch 
die (M)ACI als Vergleichsinterventionen herangezogen. Auf den Vergleich 
mit anderen möglichen chirurgischen Eingriffen, wie autologe osteochondra-
le Transplantate, wurde verzichtet. 
Der Bericht behandelt die Frage, ob der einzeitige matrix-assistierte Knorpel-
ersatz in Kombination mit der Mikrofrakturierung wirksamer und sicherer 
ist als die Mikrofrakturierung. Weiters soll die Frage beantwortet werden, ob 
der einzeitige matrix-assistierte Knorpelersatz in Kombination mit der Mik-
rofrakturierung genauso wirksam, aber sicherer als die (M)ACI ist. 
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Indikation und therapeutisches Ziel 
Im Fokus des Berichts steht die Behandlung chondraler bzw. osteochondraler 
Schäden im Kniegelenk.  
Der Gelenksknorpel ist eine dünne Gewebsschicht, die eine geschmeidige 
Oberfläche bildet, um die Beweglichkeit des Gelenks zu gewährleisten und 
um Stöße abzufangen. Eine Schädigung des Knorpels kann entweder durch 
ein Trauma (z. B. Sportunfall), durch Abnutzungserscheinungen (speziell bei 
älteren Menschen) oder durch die Osteochondrosis dissecans (OCD) entste-
hen. 
Ein Knorpelschaden kann mit Schmerzen und Bewegungseinschränkungen 
einhergehen. Bei weiterer Fortschreitung kann der Defekt zu einer degene-
rativen Osteoarthritis führen – bis hin zur Notwendigkeit eines künstlichen 
Gelenks. 
Zur Diagnose von chondralen oder osteochondralen Defekten sind, neben der 
klinischen Diagnostik (Inspektion, Palpation, Funktionstests), vor allem bild-
gebende Verfahren (Röntgen und MRT) notwendig. 
 
Methoden 
Die Beantwortung der Forschungsfragen bezüglich Wirksamkeit und Sicher-
heit basierte auf einer systematischen Literatursuche in folgenden Datenban-
ken: 
 The Cochrane Library, 
 CRD (DARE, NHS-EED, HTA), 
 Embase,  
 Medline via Ovid, 
 PubMed. 
Zusätzlich wurde noch eine Handsuche durchgeführt und es gab eine Anfrage 
nach Studien bei den einzelnen Herstellern. 
Die Studienauswahl erfolgte nach dem 4-Augenprinzip, ebenso die Datenex-
traktion. Insgesamt wurden vier Publikationen für eine Datensynthese einge-
schlossen. 
Die Daten, der für die Entscheidung herangezogenen Endpunkte, wurden 
aus den einzelnen Studien zusammengefasst und nach GRADE (Grading of 
Recommendations Assessment, Development and Evaluation) bewertet.  
Zusätzlich wurde das Bias-Risiko für jeden entscheidungsrelevanten End-
punkt nach einer Checkliste von zwei AutorInnen, unabhängig von einander, 
bewertet.  
Klinische Wirksamkeit 
Zur Bewertung der Wirksamkeit wurden die folgenden entscheidenden 
Endpunkte für eine Empfehlung herangezogen: 
 Mobilität/Gelenksfunktion 
 Lebensqualität 
 Schmerzen 
 Notwendigkeit eines Gelenksersatz 
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Sicherheit 
Zur Bewertung der Sicherheit wurden die folgenden entscheidenden  
Endpunkte für eine Empfehlung herangezogen: 
 Eingriffsbezogene Komplikationen 
 Implantatsbezogene Komplikationen 
 Reoperationsrate 
 
Ergebnisse 
Verfügbare Evidenz 
Insgesamt konnten zwei randomisierte kontrollierte Studien (RCTs) und ei-
ne nicht-randomisierte kontrollierte Studie identifiziert werden, die den Ein-
schlusskriterien entsprachen. Alle drei Studien verglichen den einzeitgen ma-
trix-assistierten Knorpelersatz (in Kombination mit der Mikrofrakturierung) 
mit der Mikrofrakturierung.  
In den eingeschlossenen Studien befanden sich 136 PatientInnen, mit einem 
Durchschnittsalter von 33-38 Jahren in den Interventionsgruppen sowie 37-
41 Jahren in den Kontrollgruppen. Die Nachbetrachtungszeit betrug 6, 24 und 
60 Monate. In den Studien wurde entweder Chondro-Gide® oder BST-Car-
Gel® eingesetzt. In einer Studie wurde nur erwähnt, dass eine Matrix aus Po-
lyethylenglycol-Diacryl verwendet wurde (ähnlich GelrinC®). 
Es konnten keine kontrollierten Studien identifiziert werden, die den einzei-
tigen matrix-assistierten Knorpelersatz (in Kombination mit der Mikrofrak-
turierung) mit der (M)ACI verglichen. 
Klinische Wirksamkeit 
Die Funktionalität des Kniegelenks wurde in allen eingeschlossenen Stu-
dien mit verschiedenen Scores gemessen (z. B. modifizierter Cincinatti Score, 
WOMAC Score und dem IKDC Score). In allen Studien konnte eine Verbes-
serung der Scores sowohl in den Interventionsgruppen als auch in den Kon-
trollgruppen festgestellt werden. Jedoch war der Unterschied der Verbesserun-
gen zwischen den Behandlungsgruppen in keiner Studie statistisch signifi-
kant. 
In einem RCT wurde erwähnt, dass während der zweijährigen Nachbeobach-
tungszeit bei einem/einer PatientIn, der/die mittels einzeitigen matrix-assis-
tierten Knorpelersatz behandelt wurde, der Einsatz eines künstlichen Knie-
gelenks notwendig war.  
Weiters wurde in einem RCT die Lebensqualität gemessen: mittels psychi-
scher und physischer Komponente des SF-36. Beide Scores konnten eine Ver-
besserung der Lebensqualität sowohl in den Interventionsgruppen als auch 
in den Kontrollgruppen festhalten. Jedoch war der Unterschied der Verbes-
serungen zwischen den Behandlungsgruppen statistisch nicht signifikant. 
Schmerzen wurden wieder in allen drei eingeschlossenen Studien mit ver-
schiedenen Scores gemessen (z. B. visuelle Analogskala). Auch die Schmer-
zen konnten sowohl in den Interventionsgruppen als auch in den Kontroll-
gruppen reduziert werden, wobei der Unterschied der Verbesserungen zwi-
schen den Behandlungsgruppen statistisch nicht signifikant war. 
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Sicherheit 
Eingriffsbezogene Komplikationen traten bei 0-93 % der PatientInnen die mit-
tels einzeitigen matrix-assistierten Knorpelersatz (in Kombination mit Mik-
rofrakturierung) und bei 0-77 % der PatientInnen, die nur mit Mikrofraktu-
rierung behandelt wurden, auf. 
Komplikationen, die mit der Implantation der Matrix in Verbindung gebracht 
wurden, traten bei 0-22 % der PatientInnen auf. 
In keiner der Studien wurde explizit berichtet, wie viele PatientInnen einer 
Reoperation unterzogen werden mussten. 
Laufende Studien 
Aktuell sind vier laufende RCTs registriert. Zwei der Studien vergleichen den 
einzeitigen matrix-assistierten Knorpelersatz mit der Mikrofrakturierung und 
zwei mit der matrix-assistierten autologen Chondrozytenimplantation (MACI).  
Kostenerstattung 
Derzeit werden in Österreich die Kosten für den einzeitigen matrix-assistier-
ten Knorpelersatz nicht separat erstattet. 
 
Diskussion 
Das Ziel des vorliegenden Berichts war es die Wirksamkeit und Sicherheit des 
einzeitigen matrix-assistierten Knorpelersatzes (in Kombination mit der Mi-
krofrakturierung) im Vergleich zur Mikrofrakturierung allein sowie zur (ma-
trix-assistierten) autologen Condrozytenimplantation ((M)ACI) zu bewerten.  
Insgesamt wurden 3 kontrollierte Studien für die Datensynthese eingeschlos-
sen, die den Einschlusskriterien entsprachen. In allen Studien wurden die Pa-
tientInnen in den Kontrollgruppen mittels Mikrofrakturierung behandelt. Die 
Evidenzstärke der Studien war generell gering. 
Keine der Studien konnte eine Überlegenheit des einzeitigen matrix-assis-
tierten Knorpelersatz belegen. Die Studien suggerieren eher eine Gleichwer-
tigkeit, im Vergleich zu alleinigen Mikrofrakturierung. 
Kritikpunkte der identifizierten Studien sind vor allem die relativ kurzen 
Nachbeobachtungszeiträume und die kleinen PatientInnenzahlen in der Mehr-
zahl der Studien. Ein weiterer Kritikpunkt sind die inkonsistenten Angaben 
zu Komplikationen, was sich insbesondere in den unterschiedlich hohen Ra-
ten widerspiegelt. Außerdem wichen die einzelnen Interventionen in den Stu-
dien geringfügig voneinander ab (Art der verwendeten Matrix und Fixierung 
der Matrix im Defekt, etc.). 
Entscheidende Schwächen des vorliegenden Berichts sind insbesondere: der 
konsequente Ausschluss von Ein-Arm-Studien, die weniger als 50 PatientIn-
nen untersuchten und eine Nachbeobachtungszeit von weniger als zwei Jahren 
hatten. Außerdem der Ausschluss von Studien, in denen nicht ausschließlich 
der einzeitige matrix-assistierte Knorpelersatz in Kombination mit der Mik-
rofrakturierung vorgenommen wurde. Sowie der Ausschluss von Studien die 
retrospektiv angelegt waren (dazu zählten auch Studien mit einer historischen 
Kontrollgruppe). 
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Empfehlung 
Die gegenwärtige Studienlage lässt keine Rückschlüsse zu, ob der einzeitige 
matrix-assistierte Knorpelersatz (in Kombination mit der Mikrofrakturierung) 
wirksamer und sicherer als die Mikrofrakturierung allein, bzw. mindestens 
genauso wirksam, aber sicherer im Vergleich zur (M)ACI ist. 
Weitere Studienergebnisse, insbesondere von Studien mit längeren Nachbe-
obachtungszeiträumen sowie größeren Fallzahlen könnten die Ergebnisse be-
einflussen. 
Die Aufnahme in den Leistungskatalog wird derzeit nicht empfohlen. Eine 
neuerliche Re-Evaluierung wird für frühestens 2018 vorgeschlagen.  
 
kein Beweis, dass 
wirksamer und sicherer 
als Mikrofrakturierung 
weitere Studien nötig 
Aufnahme in den 
Leistungskatalog derzeit 
nicht empfohlen 
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1 Scope 
1.1 PICO question 
1) Is the single-step scaffold-based cartilage repair in combination with micro-
fracturing more effective and safe in comparison to microfracturing alone in 
patients with indications for cartilage knee surgery concerning the outcomes 
listed in Table 1-1? 
2) Is the single-step scaffold-based cartilage repair in combination with micro-
fracturing as effective, but safer in comparison to two-step cartilage repair pro-
cedures (autologous chondrocyte implantation or matrix-induced autologous 
chondrocyte implantation (M)ACI)) in patients with indications for cartilage 
knee surgery concerning the outcomes listed in Table 1-1? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population  Adult patients with indications for surgical cartilage repair in the knee 
 Grade III to IV (Outerbridge classification) localised cartilage 
damages/defects/disorders in the knee  
 Grade III to IV (ICRS classification) (osteo)chondral lesions 
 Osteochondritis dissecans (OCD)  
 Contraindications: 
 Defect size <1 and >8 cm² 
 Allergies of the used material(s) 
 Inflammatory cartilage diseases 
 Malposition of the knee ≥5 degrees 
ICD-10 codes:M24.1, M94.8, M94.9, M93.2 [1] 
Intervention  Single-step cell-free scaffold-based cartilage repair in combination with microfracturing 
 Alternative terms (selection): 
 Autologous matrix-induced chondrogenesis (AMIC) 
 Cell-free matrix-induced chondrogenesis 
 Cell-free (collagen) matrices/matrix 
 Product names: 
 BST-CarGel® 
 CaReS®-1S 
 Condro-Gide® 
 Chondrotissue® 
 GelrinC® 
 Hyalofast® 
 MaioRegenTM 
 MeRG® 
 
PIKO-Frage Teil 1 
PIKO-Frage Teil 2 
Einschlusskriterien  
für relevante Studien 
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Control  Microfracture surgery/microfracturing alone (main comparator) 
 Autologous chondrocyte implantation/transplantation (ACI/ACT) 
 Matrix-induced autologous chondrocyte implantation (MACI) 
Outcomes  
Efficacy  Mobility/joint functionality 
 Pain 
 Return to daily activities/sports/physical activity 
 Quality of life 
 Neccessity of total joint replacement 
Safety  Adverse events 
 Mortality (up to 10 days postoperatively) 
 Re-operation/additional surgery 
Study design  
Efficacy  Randomised controlled trials 
 Prospective non-randomised controlled trials 
Safety  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 Prospective uncontrolled trials (n>50 pts., follow-up>24 months) 
 
 
 
 LBI-HTA | 2016 15 
2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is the technology and the comparators? 
A0020 For which indications has the technology received marketing authorisation or CE marking? 
B0002 What is the claimed benefit of the technology in relation to the comparators? 
B0004 Who administers the technology and the comparators and in what context and level of care 
are they provided? 
B0008 What kind of special premises are needed to use the technology and the comparator(s)? 
B0009 What supplies are needed to use the technology and the comparator(s)? 
A0021 What is the reimbursement status of the technology 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is the technology used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for the disease or health condition? 
A0004 What is the natural course of the disease or health condition? 
A0005 What is the burden of disease for the patients with the disease or health condition? 
A0006 What are the consequences of the disease or health condition for the society? 
A0024 How is the disease or health condition currently diagnosed according to published guidelines 
and in practice? 
A0025 How is the disease or health condition currently managed according to published guidelines 
and in practice? 
A0007 What is the target population in this assessment?  
A0011 How much are the technologies utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0005 How does the technology affect symptoms and findings (severity, frequency) of the disease 
or health condition? 
D0006 How does the technology affect progression (or recurrence) of the disease or health condition? 
D0016 How does the use of technology affect activities of daily living? 
D0012 What is the effect of the technology on generic health-related quality of life? 
D0013 What is the effect of the technology on disease-specific quality of life? 
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Safety 
Element ID Research question 
C0008 How safe is the technology in comparison to the comparator(s)? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the 
use of the technology? 
C0007 Are the technology and comparator(s) associated with user-dependent harms? 
 
 
2.2 Sources 
To answer the research questions, the results from the systematic literature 
search (see Section 2.3) and from the hand search were used. 
Description of the technology 
 Handsearch in the POP database for Health Technology Assessments 
and in Google (for identifying manufacturers and product information) 
 Publications identified in systematic database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospitals  
Health problem and Current Use 
 Handsearch in the POP databases for Health Technology Assessments 
and in Google 
 Publications identified in systematic database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospitals  
 
 
2.3 Systematic literature search 
The systematic literature search was conducted between  
13th and 15th of January 2016 in the following databases:  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
 Embase  
 Medline via Ovid 
 PubMed 
The systematic search was limited to articles published in English or Ger-
man. After deduplication, overall 267 citations were included. The specific 
search strategy employed can be found in the appendix. 
Manufacturers from the most common products (see Chapter 3, Element ID 
B0001 – What is the technology and the comparators?) submitted 46 publi-
cations of which 14 new citations were identified. By hand-search, additional 
183 records were found (164 were found by a Scopus-search, based on four 
studies), resulting in overall 464 hits. 
Quellen:  
systematische Suche, 
Handsuche, aber auch 
Informationen der 
Hersteller 
systematische 
Literatursuche in fünf 
Datenbanken  
Systematische Suche: 
267 Zitate 
insgesamt  
464 Publikationen 
identifiziert 
Methods 
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2.4 Flow chart of study selection 
Overall 464 hits were identified. The references were screened by two inde-
pendent researchers and in case of disagreement a third researcher was in-
volved to solve the differences. The selection process is displayed in Figure 
2-1. Articles that were excluded due to several reasons but still used as back-
ground are categorized under “background literature”. Furthermore, we were 
not able to retrieve the full-texts of five articles. These are categorized under 
“not available”. 
 
*Two publications presented results of one RCT. Therefore, data from both publications are presented together. 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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through other sources  
(n=229) 
Records after duplicates  
removed 
(n=464) 
Records screened 
(n=464) 
Records excluded 
(n=392) 
Full-text articles  
assessed for eligibility 
(n=72) 
Full-text articles excluded,  
with reasons 
(n=68) 
 Background literature (n=38) 
 Wrong population (n=1) 
 Wrong intervention (n=10) 
 Not available (n=5) 
 Wrong study design (n=14) 
 Retrospective (n=2) 
 Case series <50 patients (n=9) 
 Follow-up <24 months (n=1) 
 No clinical trial (n=2) 
Studies included in 
qualitative synthesis 
(n=4) 
 RCTs (n=3*) 
 NRCTs (n=1) 
 Case-series (n=0) 
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2.5 Analysis 
The data retrieved from the selected studies (see Chapter 2.4) were systemat-
ically extracted into a data-extraction-table (see Appendix). No further data 
processing (e.g., indirect comparison) was applied. The studies were system-
atically assessed for quality and risk of bias using the checklists presented in 
the Appendix. 
 
 
2.6 Synthesis 
Based on the data-extraction-tables (see Appendix), data on each selected 
outcome category were qualitatively synthesised across studies according to 
GRADE (Grading of Recommendations Assessment, Development and Eval-
uation) [2]. The research questions were answered in plain text format with 
reference to GRADE evidence tables (see Chapter 7).  
 
 
Datenextraktion und 
Bewertung Bias-Risiko  
laut Checkliste 
Evidenzsynthese  
mittels GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is the technology and the comparators? 
There are different approaches available for the single-step scaffold-based car-
tilage repair [3, 4]. However, the procedure is mainly an enhancement of the 
standard microfracture technique, used to induce reparative marrow-stimula-
tion. Other reparative bone-marrow stimulation techniques, such as drilling, 
are not considered in this report, as microfracture is the established standard 
[4, 5]. Thus, we exclusively focus on one approach, where the implantation of 
the scaffold is combined with microfracture (MFx). 
Microfracture consists in the perforation of the subchondral bone of the ar-
ticular cartilage defect, leading to the formation of a blood clot and egress of 
marrow components, including stem cells and growth factors that stimulate 
chondrogenesis and cartilage repair [6, 7]. 
In the single-step scaffold-based treatment of cartilage defects, a matrix is im-
planted in the area of the damaged cartilage to cover the blood clot after MFx. 
This technique is also called autologous matrix-induced chondrogenesis (AM-
IC) [6-9]. The acronym AMIC is originally a registered trademark of the Ed. 
Geistlich Söhne AG (Schlieren, Switzerland) [9]. 
The scaffolds are implanted arthroscopically or by a mini-arthrotomy for “in 
situ” repair, permitting the ingrowing of mesenchymal stem cells (MSCs) to 
differentiate into the chondrogenic lineage. The used matrix acts as a tem-
porary structure to allow the cells to be seeded and establish a 3-dimensional 
structure. The matrices decompose over time [10]. 
The used matrices are cell-free scaffolds, such as a porcine collagen matrix. 
However, material and configuration of the scaffolds vary between the indi-
vidual products [11, 12].  
We found eight products from eight manufacturers, which will be further ex-
plained below. All products have in common that bone marrow is intended 
to colonise/seed the matrix. 
BST-CarGel®  
BST-CarGel® (Primal Enterprises Limited, Canada)1 is a gel that consists of 
a chitosan solution (a natural polymer) and a buffer. BST-CarGel® must be 
used in combination with a bone marrow stimulation technique (e.g. micro-
fraturing). During the cartilage repair surgery, the gel is applied to the le-
sion and mixed with the blood generated from the bone marrow stimulation. 
BST-CarGel® is only indicated for the repair of cartilage damage in the knee 
(contra-indications were not identified) [13].  
 
                                                             
1 On January 12, 2016 Piramal Enterprises announced the sale of the product BST-
CarGel® to Smith and Nephew (UK). 
Fokus auf ein Verfahren 
für Knorpelreparatur  
in Kombination mit 
Mikrofrakturierung 
Mikrofrakturierung 
stimuliert Knochenmark 
Technik auch als AMIC 
bezeichnet 
Matrix als 
Unterstützung  
für Zellansiedlung 
Matrix ist zellfrei 
acht verschiedene 
Produkte 
BST-CarGel®  
ist Hydrogel  
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CaReS®-1S 
CaReS®-1S (Arthro Kinetics AG, Germany) is a collagen type I matrix for the 
treatment of chondral lesions. This implant is inserted (by gluing) in the de-
fect zone and is colonised by cells migrating from the surrounding tissue af-
ter bone marrow stimulation (e.g. microfracturing). Exemplary contra-indi-
cations for the use of CaReS®-1S are: defect sizes >8 cm², age younger 18 and 
older 60, BMI >35 kg/m² [14]. 
Chondro-Gide® 
Chondro-Gide® (Geistlich Pharma, Switzerland) is a bilayer matrix made from 
porcine collagen type I/III for the treatment of traumatic chondral and osteo-
chondral lesions [15]. Besides AMIC, the product can also be used for MACI 
(matrix-assisted autologous chondrocyte implantation). Chondro-Gide® is in-
serted in the damaged area (by gluing or suturing), after microfracturing. The 
clot formed as a result of haemorrhage is covered and stabilised by the scaf-
fold. Exemplary contra-indications for the use of Chondro-Gide® are: defect 
sizes >8 cm², age older 60, more than two or corresponding cartilage defects, 
systemic, immune mediated disease or infection of the knee including osteo-
arthritis, inflammatory joint reactions, instable knee, menisectomy, varus/ 
valgus (concomitant realignement procedure required), hemophilia A/B or al-
lergy to porcine collagen [15].  
Chondrotissue® 
Chondrotissue® (BioTissue Technologies GmbH, Switzerland) is made from 
polyglycolic acid fleece and freeze-dried sodium hyaluronate for the treatment 
of chondral lesions. The scaffold is implanted (by gluing, suturing or nailing) 
into the area of the defective cartilage after bone marrow stimulation proce-
dures (e.g. microfracturing). Exemplary contra-indications for the use of Chon-
drotissue® are: allergies to one of the constituents, when patients have to un-
dergo chemotherapy and/or radiotherapy up to three weeks after the implant, 
children or pregnant and lactating women, or patients with inflammatory joint 
diseases, such as rheumatoid arthritis and Bechterew’s disease [16].  
GelrinC® 
GelrinC® (Regentis Biomaterials Ltd., Israel) is a hydrogel of polyethylene 
glycol di-acrylate (PEG-DA) and denatured fibrinogen, crosslinked with UVA 
light in-situ, for the treatment of chondral defects. The gel is applied into the 
defective cartilage after bone marrow stimulation procedure, typically micro-
fracture [17]. Unfortunately, no information on contra-indications for the use 
of GelrinC® has been identified.  
Hyalofast® 
Hyalofast® (Anika Therapeutics, Inc., USA) is a biodegradable, hyaluronan 
based (HYAFF®) scaffold. Hyalofast® is intended for the repair of chondral or 
osteochondral lesions, acting as a support for mesenchymal stem cells (MSC) 
from bone marrow aspirate or as a chondroprotective coverage which favours 
in situ residence of mesenchymal stem cells after their mobilization due to 
microfracture and/or perforation procedure [18]. Unfortunately, no informa-
tion on contra-indications for the use of Hyalofast® has been identified. 
MaioregenTM 
MaioregenTM (Fin-Ceramica Faenza S.p.A., Italy) is a multi-layer scaffold: 
the superficial layer consists of deantigenated type I equine collagen and re-
sembles the cartilaginous tissue, while the lower layer consists mostly of mag-
CaReS®-1S ist  
Kollagen-Matrix 
Chondro-Gide® ist 
Kollagen-Matrix 
Chondrotissue® Matrix 
aus Polyglykolsäure-Filz 
und Hyaluronsäure 
GelrinC® ist  
Hydrogel 
Hyalofast® Matrix  
aus Hyaluronsäure 
MaioregenTM  
Matrix aus Kollagen  
und Hydroxylapatit 
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nesium-enriched hydroxyapatite (Mg-HA) and simulates the sub-chondral bone 
structure. The intermediate layer, composed of Mg-HA and collagen, repro-
duces the tide-mark [19]. The scaffold is implanted (by gluing) into the area 
of the defective chondral or osteochondral defect. For the treatment of osteo-
chondral defects, the bone marrow stimulation (e.g. microfracturing) or ad-
dition of marrow concentrate is not necessary. MaioregenTM should not be 
used in patients with advanced osteoarthritic conditions, immune system dis-
orders, neoplastic diseases, infectious diseases, obesity (BMI > 30), or above 
60 years of age [19]. 
MeRG® 
MeRG® (Bioteck S.p.A., Italy) is a microfibrillar collagen membrane that is 
inserted in the chondral lesion after microfracture. The fixation can be done 
by gluing. The scaffold protects and shields the cells to form new tissue. The 
only reported contra-indication of MeRG® is a hypersensitivity to collagen [20]. 
Comparators 
For small cartilage lesions, microfracture surgery alone (or microfracturing) 
is considered the gold standard (information from the submitting hospital). 
Thus, the main comparator in this review is microfracture surgery alone 
For larger defects (>2.5 cm² according to the submitting hospital), the autol-
ogous chondrocyte implantation (ACI) is indicated, which may also be used 
in combination with a matrix (MACI). Thus, (M)ACI was considered as an 
additional comparator. 
The individual interventions are further explained in Chapter 4 (Element ID 
A0025 – How is the disease or health condition currently managed according 
to published guidelines and in practice?).  
A0020 – For which indications has the technology received  
marketing authorisation or CE marking? 
There are different manufacturers providing several products for single-step 
matrix-assisted cartilage repair, whereas all products have marketing author-
isation within Europe (CE mark).  
The different products of the individual manufacturers and the year of CE 
approval are summarised in the following table. 
Table 3-1: Overview of European marketing authorisation of individual products 
Product Manufacturer CE marking 
BST-CarGel® Primal Enterprises Limited Yes (2014) 
CaReS®-1S Arthro Kinetics AG Yes (year unknown) 
Chondro-Gide® Geistlich Pharma Yes (2010) 
Chondrotissue® BioTissue Technologies GmbH Yes (year unknown) 
GelrinC Regentis Biomaterials Ltd. Yes (2013) 
Hyalofast® Anika Therapeutics, Inc. Yes (2009) 
MaioregenTM  Fin-Ceramica Faenza S.p.A. Yes (year unknown) 
MeRG® Bioteck S.p.A. Yes (2012) 
References: individual manufacturers’ websites 
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B0002 – What is the claimed benefit  
of the technique in relation to the comparators? 
Single-step treatment by the use of a scaffold is a technique for the repair of 
chondral or osteochondral defects. The technique is intended to achieve pain 
relief and to restore the functionality of the affected joint to regain mobility 
and previous lifestyle – like all interventions for cartilage repair [9, 21].  
Furthermore, the technique aims at slowing down joint degeneration with the 
intent to avoid or delay osteoarthrosis and partial or total joint replacement 
surgery [8, 11]. 
The scaffold-based single-step treatment of cartilage damages is used as an 
add-on intervention to microfracturing. Thus, the procedure enables the treat-
ment of larger cartilage defects than microfracturing alone. Furthermore, a 
better microenvironment and structure for cell proliferation has been stipu-
lated for the scaffolds, compared to microfracturing alone [3, 10]. 
In comparison to (M)ACI, the technique claims the advantage of the single-
step procedure, sparing the need for a second intervention (one for biopsy and 
one for the implant), resulting in fewer complications and lower costs, but at 
comparable effectiveness with regards to clinical outcomes [22, 23].  
 
Administration, Investments, personnel and tools  
required to use the technology and the comparator(s) 
B0004 – Who administers the technology and the comparators  
and in what context and level of care are they provided? 
The single-step treatment by the use of a scaffold and also microfracturing and 
(M)ACI should be performed by an orthopaedic surgeon with the support of 
two persons of the nursing staff. The procedures can be done under general 
or spinal anaesthesia. Microfracturing, the single-step treatment by the use 
of a scaffold, and (M)ACI can be done in an outpatient facility [3, 9, 11, 22]. 
B0008 – What kind of special premises are needed  
to use the technology and the comparator(s)? 
For all surgical interventions of chondral or osteochondral repair a sterile op-
eration theatre is suggested. Moreover, several instruments are required. Ad-
ditionally, for the single-step treatment and for MACI, the matrix is needed 
to allow the cells to be seeded (see also Element ID B0001) [5, 11, 22, 24]. 
Furthermore, for (M)ACI, a laboratory is needed for cell culturing and ex-
pansion (see also Element ID B0001) [25]. 
B0009 – What supplies are needed to use AMIC and the comparator(s)? 
See Element ID B0008. 
 
  
Schmerzlinderung, 
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Funktion 
Verlangsamung 
Gelenkabnutzung 
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Regulatory & reimbursement status  
A0021 – What is the reimbursement status of AMIC? 
At this point in time, the single-step scaffold-based repair of cartilage defects 
or osteochondritis dissecans (OCD) or (osteo)chondral lesions in the knee 
joint is not included in the Austrian hospital benefit catalogue. Therefore, the 
intervention itself is not reimbursed by the Austrian health care system. How-
ever, the intervention could be billed under another code, like for arthroscopic 
operations of the knee joint (Code NF020 – Arthroskopische Operationen des 
Kniegelenks). 
 
  
Intervention in 
Österreich derzeit  
nicht erstattet 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions,  
and for what purposes is the technology used? 
The scaffolds described in chapter 3 (Element ID B0001 – What is the tech-
nology and the comparators?) are intended for the treatment of articular chon-
dral or osteochondral lesions [4, 6, 11].  
A0002 – What is the disease or health condition  
in the scope of this assessment?  
This systematic review will focus on the treatment of chondral and osteochon-
dral lesions in the knee. 
A0003 – What are the known risk factors for the disease  
or health condition? 
Articular (chondral) cartilage is a thin layer of connective tissue. It provides 
a smooth surface for articulation and facilitates the transmission of forces to 
the underlying subchondral bone.  
A damage of the cartilage can occur due to traumatic events, degeneration of 
the joint or due to osteochondritis dissecans (OCD). The damage can also af-
fect the underlying bone (i.e. osteochondral lesion) [3, 4, 25]. 
For instance, traumatic events can be caused by sport injuries (e.g. ski acci-
dents), or incorrect weight-bearing. Altered biomechanics within the joint, due 
to previous injuries and/or surgical interventions can also play a role. [24, 26].  
Moreover, degenerative cartilage damage of the joint is common in elderly 
people. Due to the abrasion, particularly in the weight-bearing joints, over the 
years, structural integrity of the cartilage surface (and eventually also the un-
derlying bone) can be affected [8, 24].  
Osteochondritis dissecans – an acquired idiopathic lesion of subchondral bone 
characterised by osseous resorption, collapse, and sequestrum formation – can 
possibly involve the damage of articular cartilage [4]. Thus, OCD is also a 
cause for an osteochondral lesion and defective cartilage. 
A0004 – What is the natural course of the disease or health condition? 
A chondral and osteochondral lesion is a debilitating condition. The damage 
can occur in nearly every phase of life. However, besides older people (with 
degenerative cartilage damage), especially young and active people are likely 
to acquire chondral or osteochondral lesions. Due to the low intrinsic healing 
capacity of human articular cartilage, spontaneous healing of the damaged 
tissue cannot be expected. Besides pain and functional impairment, cartilage 
lesions can lead to the development of osteoarthritis [11, 26]. 
There are various grading systems for (osteo)chondral defects and OCD, main-
ly determined by the type of diagnostic examination (e.g. MRI or arthroscopy) 
[27-29]. The classification systems – mainly used in German speaking coun-
tries – are shown in the following four tables. 
Behandlung chondraler 
oder osteochondraler 
Schäden 
Fokus auf Schäden  
in Kniegelenk 
Knorpel ist dünne 
Gewebsschicht 
mehrere Ursachen: 
durch Trauma 
durch Abnutzung 
durch Osteochondritis 
dissecans 
(Knochen-)Knorpel-
schaden vor allem bei 
älteren und jungen, 
sportlich aktiven 
Menschen 
verschiedene 
Klassifikations-Systeme 
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Table 4-1: Classification of chondral defects by ICRS 
Grade/stage Characteristics 
0 Normal 
1 Nearly normal  
(soft indentation and/or superficial fissures and cracks) 
2 Abnormal (lesions extending down to <50% of cartilage depth 
3 Severely abnormal (carilage defects >50% of cartilage depth 
4 Severely abnormal (through the subchondral bone) 
Reference: [27] 
Table 4-2: Classification of chondral defects by Outerbridge 
Grade/stage Characteristics 
0 Normal 
1 Softening and swelling of cartilage 
2 Fragmentation and fissuring, less than 1.5 cm-in diameter 
3 Fragmentation and fissuring, greater than 1.5 cm in diameter 
4 Erosion of cartilage down to exposed subchondral bone 
Reference: [27] 
Table 4-3: Classification of OCD/osteochondral defects by Kramer  
Grade/stage Characteristics 
1 Bone marrow oedema 
2 Demarked bone, possibly altered cartilage 
3 Partial osteochondral fissure, partial discontinued cartilage 
5 Entire osteochondral fissure, completely discontinued cartilage 
6 Dislocated OCD 
Reference: [28] 
Table 4-4: Classification of OCD/osteochondral defects by Guhl 
Grade/stage Characteristics 
1 Normal articular cartilage 
2 Fragmentation in situ 
3 Partial detachment 
4 Complete detachment, loose body present 
Reference: [30] 
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Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease  
for patients with the disease or health condition? 
Patients with chondral and osteochondral defects are suffering from pain and 
impaired mobility, leading to a lower quality of life [8].  
In addition, the chondral or osteochondral lesion can lead to the development 
of degenerative osteoarthritis and a further progression can lead to the re-
quirement of a joint replacement [11, 24].  
A0006 – What are the consequences of the disease  
or health condition for the society? 
In 2014 in Austria, nearly 80,000 surgeries of the knee joint were performed 
[31]. However, no information regarding the prevalence or incidence of car-
tilage disorders or OCD (especially for Grade 3-4 of the Outerbridge classifi-
cation) have been identified. 
 
Current clinical management of the disease or health condition 
A0024 – How is the disease or health condition currently diagnosed 
according to published guidelines and in practice? 
No Austrian guidelines for the diagnosis (and treatment) of (osteo)chondral 
defects or OCD were identified. We identified two international guidelines 
for the treatment of OCD and one for articular cartilage lesions [32-34].  
First of all, there should be a physical examination of the affected joint. This 
includes an inspection (swelling of the joint, gait, etc.), palpation (pressure 
pain, extrusion in the joint, etc.) and specific tests for functioning and pain 
(motion, Wilson’s test2, etc.) [32-34]. 
As a second step, the affected joint should be examined by diagnostic imag-
ing, i.e. X-rays and/or magnetic resonance imaging (MRI) [32, 33, 35].  
X-rays provide detailed pictures of dense structures, like bone. An X-ray of 
the affected joint is essential to clarify if the underlying bone is also affected 
[32, 33, 35]. 
In comparison to X-rays, MRI can create better images of soft tissues like car-
tilage. An MRI should be performed in addition to X-Ray to evaluate the ex-
tent to which the overlying cartilage is affected [32, 33, 35]. 
Alternative diagnostic imaging techniques, like ultrasound, computed tomo-
graphy, or arthroscopy can also be used [32, 33]. 
A0025 – How is the disease or health condition 
currently managed according to published guidelines and in practice? 
There are numerous treatment options for (osteo)chondral lesions or OCD, 
starting with conservative treatment and followed by surgical interventions 
[32-35].  
                                                             
2 Pain with internally rotating the tibia during extension of the knee between 90° and 
30°, then relieving the pain with tibial external rotation. 
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Generally, the treatment of chondral or osteochondral lesions aims at pain re-
duction, regaining joint mobility, reactivation of the affected area, prevent-
ing/slowing of the progression and prevention of osteoarthritis, and eventu-
ally avoiding total joint replacement [32, 34, 35].  
Conservative treatment includes physical therapy (e.g. progressive knee mo-
tion), partial weight-bearing or activity restrictions and pain management [32-
35]. 
A variety of surgical techniques and associated devices have evolved, aiming 
at resurfacing and repairing the (osteo)chondral lesions. However, none of the 
identified guidelines recommends one specific surgical intervention. The ap-
plication of the individual techniques depends on several factors, like defect 
size (or grade) and localisation, age of the patient, or grade of discomfort [32, 
33, 35]. 
Arthroscopic lavage (or debridement) is a “cleaning up” procedure of the (knee) 
joint. This intervention is a short term solution and is not considered as a 
chondral repair procedure. Lavage is rather a palliative treatment to reduce 
pain, mechanical restriction, and inflammation. Lavage focusses on removing 
degenerative articular cartilage flaps and fibrous tissue [6, 21]. 
During bone marrow stimulating techniques (e.g. microfracuring), damaged carti-
lage is drilled or punched until the underlying bone is exposed. Thereby, the 
subchondral bone is perforated to generate a blood clot within the defect [7]. 
Microfracturing (MFx) is a repair surgical technique that works by means of 
creating tiny fractures (e.g. by drilling) in the subchondral bone. The under-
lying idea is to promote cartilage regeneration from a so-called “super-clot” 
(after bleeding from the bone marrow). The surgery is performed by arthros-
copy after the joint is cleaned of calcified cartilage. Microfracturing has been 
declared the first-line treatment for focal cartilage defects by various sources. 
However, the procedure seems less effective in treating older patients, over-
weight patients, or cartilage lesions larger than 2.5 cm² [7, 24]. 
ACI (or ACT) is performed in different steps. In a first step, intact cartilage 
is sampled arthroscopically from a non-weightbearing area of the affected 
cartilage. The generated cells are then cultured in vitro until there are enough 
cells to be re-implanted into the cartilage lesion. These autologous cells should 
adapt themselves to their new environment by forming new tissue. If chon-
drocytes are applied onto the damaged area in combination with a membrane 
(tibial periosteum or biomembrane) or pre-seeded in a scaffold matrix, this 
technique is called MACI. The intention of (M)ACI is to treat larger defect 
sizes than MFx [24-26].  
Another treatment option is autologous osteochondral transplantation (osteoar-
ticular transfer system or mosaicplasty). During mosaicplasty (MP), the un-
healthy tissue is removed to leave the healthy bone underneath. The surgeon 
obtains the healthy tissue, for instance from a non-weight-bearing area, which 
will be placed into the holes in the joint until it forms a smooth surface. It may 
require multiple plugs to fill the gaps in the joint surface. This gives the re-
paired surface the appearance of a mosaic. The intervention can be done ar-
throscopically. However, MP is intended for the treatment of small sized le-
sions (up to 2 cm²) [6, 21]. Since MFx is declared as the first-line treatment 
of small cartilage damages, we did not consider MP as a comparator. 
In later stages of (osteo)chondral lesions, especially associated with an exten-
sive bone loss, patients can be treated by osteochondral allografts (coming 
from a donor) or by a total knee/joint replacement [6]. 
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Target population 
A0007 – What is the target population in this assessment? 
The target population in this assessment are patients with chondral or osteo-
chondral lesions (or OCD).  
However, there are several population restrictions given by the individual 
manufacturers of the matrices (see Chapter 3). A selection is provided below, 
representing the most overlapping specifications [14, 15, 19]: 
 ICRS or Outerbridge classification Grade 3 and 4 
 Defect size 1-8 cm² 
 Age 18+ (some manufacturers have also restrictions regarding  
a maximum age) 
 Patients without two or more corresponding cartilage defects  
or an allergy to one of the scaffold components. 
A0011 – How much is the technology utilised? 
Based on the information given on the VAEV, the estimated annual utilisa-
tion of the matrix-assisted single-step scaffold-assisted cartilage repair in the 
submitting hospital is around 15. 
There is no information provided regarding the estimated annual utilisation 
in Austria.  
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Mobility/joint functionality 
 Quality of life 
 Pain 
 Necessity of a total joint replacement 
The outcomes chosen represent the aims of a treatment of chondral and os-
teochondral defects (see Element ID A0005 – What is the burden of disease  
for patients with the disease or health condition?): pain reduction, regaining 
joint mobility, reactivation of the affected area, prevention/delay of disease 
progression, and prevention of osteoarthritis and/or avoiding total knee re-
placement. 
Mobility or joint functionality (before and after the intervention)  
can be measured by different scores [29]: 
 Knee Injury and Osteoarthritis Outcome Score (KOOS), 
 International Knee Documentation Committee (IKDC)  
Subjective Knee Form, 
 Western Ontario McMaster Universities Osteoarthritis Index 
(WOMAC), 
 Modified Cincinnati Knee Rating System, 
 Short Form 36 (SF-36), 
 Lysholm scoring scale, 
 Modified International Cartilage Repair Society (ICRS) Score. 
Quality of life can also be measured by several scores, like the EQ-5D and the 
Short-Form Health Survey (SF-36, SF-12, SF-8).  
Pain was defined as another crucial outcome, since it is considered a main 
contributor to symptom burden in patients suffering from (osteo)chondral 
defects. It can be measured with several instruments, e.g. dedicated visual 
analogue pain scales (VAS). 
The individual scores to measure joint functionality or mobility, quality of 
life, and pain will be further explained later in this chapter and in the evi-
dence tables (see Appendix) where applicable. 
Since one major aim of the treatment of chondral and osteochondral defects 
is to avoid progression of the disease and joint replacement, the necessity of 
a joint replacement was considered as a crucial long-term outcome. 
A further outcome that was not considered crucial, but was used to answer 
the effectiveness-related research questions in this chapter is “return to ac-
tivities” (like sports or daily activities). 
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5.2 Included studies 
For evaluating efficacy-related outcomes, we exclusively considered RCTs and 
prospective non-randomised controlled trials (see Chapter 1.2). 
We could not identify any controlled trials comparing the single-step scaf-
fold-assisted treatment of (osteo)chondral defects in the knee with (M)ACI.  
The only studies that met our inclusion criteria were two randomised con-
trolled trials3 (RCTs) [36-38] and one non-randomised controlled trial (non-
randomised CT) [39] with a total of 136 patients assessing the clinical effec-
tiveness of the single-step scaffold-assisted chondral repair in the knee joint 
(scaffold-groups) in combination with microfracturing (MFx), compared to 
MFx alone (MFx-groups) [36-39]. 
The mean age of patients ranged from 33 to 38 years in the treatment groups 
and from 37 to 41 years in the control groups across trials. Between 15 and 44% 
of the patients in the scaffold-groups and 20-36% of the patients in the con-
trol groups were females across trials. Patients had grade 3 to 4 (Outerbridge 
Classification) of chondral defects with a mean lesion size of 2.3-3.7 cm² in the 
scaffold-groups and 2-2.9 cm² in the control groups. The follow-up of the stud-
ies was 6, 24 and up to 60 months (5 years) [36-39]. 
In one study, it was Chondro-Gide® [37], in another BST-CarGel® [36, 38], 
and in the third study, a polyethylene glycol diacylate hydrogel (comparable 
to GelrinC®) that were applied [39].  
There were no studies assessing the clinical effectiveness of other products, 
like CaReS®-1S, Chondrotissue®, MaioregenTM or MeRG® (see Chapter 3) that 
met our inclusion criteria. 
Study characteristics and results of included studies are displayed in Table 
A-1 and in the evidence profile in Table 7-1. 
 
 
5.3 Results 
Morbidity 
D0005 – How does the technology affect symptoms and findings 
(severity, frequency) of the disease or health condition? 
Answering this research question was based on the outcome “mobility/joint 
functionality”. 
Single-step scaffold-based treatment + MFx vs. MFx 
The effect on mobility or joint functionality was measured in all three con-
trolled trials by five different scoring systems, comparing the scaffold-based 
single-step cartilage repair plus microfracturing with microfracturing alone 
[36-39]. 
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In one RCT with 28 patients and two scaffold groups (one group received a 
glued, the other group a sutured scaffold), the joint functionality was meas-
ured with the Modified Cincinnati Score4 (scale: 6-100) and with (a modified) 
ICRS Score5 [37]. The Modified Cincinnati Score increased in all study groups 
over time. After 24 months, the score improved by 46 and 37 points in both 
treatment groups and by 44 points in the control group. The difference of the 
change between the study groups was statistically not significant. For the 
change of the ICRS Score, it was only stated that there were no statistically 
significant differences between the study groups after 12 and 24 months of 
follow-up, without reporting numerical results [37]. 
In the second RCT, joint functionality was measured with the WOMAC6 sub-
scale scores for stiffness (scale: 0-20) and for function (scale: 0-170). After 12 
months, the score for stiffness improved by nearly 6 points in the treatment 
group and by ca. 6.6 points in the control group. After 60 months (compared 
to baseline), the score improved by 5.6 points in the treatment group and by 
6.7 points in the control group. The score for function improved in both study 
groups over time. After 60 months, the score improved by ca. 57 points in the 
scaffold-group and by ca. 62 points in the MFx-group. The changes of WOM-
AC sub-scores between the study groups were statistically not significant at 
any time point [36, 38]. 
In the non-randomised CT, joint functionality was measured with the IKDC 
Score7. However, it was only stated that there were no statistically signifi-
cant differences of the score changes between the study groups after 3 and 6 
months of follow-up [39]. 
Single-step scaffold-based treatment + MFx vs. (M)ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on “mobility or joint function-
ality”, compared to (M)ACI.  
D0006 – How does the technology affect progression (or recurrence)  
of the disease or health condition? 
To answer this research question, the outcome “necessity of a total joint re-
placement” was used to measure the progression of the disease. Thus, the 
higher the rate of the total joint replacement, the less is the effect of the in-
tervention of the disease progression. 
                                                             
4 The Modified Cincinnati Score consists of three parts: knee function (6-30 points), 
clinical pathology (0-20 points), highest activity level without pain (0-50 points). 
5 The Modified ICRS (International Cartilage Repair Society) Score consists of ratings 
by the patient (pain, functional status of knee) and the surgeon (functional status 
knee, classification + crepitation). 
6 The WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) 
scoring system includes pain, stiffness, and physical function, measured on a visual 
analogue scale (VAS).  
7 The IKDC (International Knee Documentation Committee) scoring system includes 
10 items investigating symptoms, function, and return to sporting activities. 
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Single-step scaffold-based treatment + MFx vs. MFx 
The necessity of a total joint replacement was reported in one RCT with 28 
patients and 24 months of follow-up. In one patient who received a (glued) 
scaffold, the knee joint had to be replaced. In none of the patients who un-
derwent MFx alone, the joint had to be replaced (likewise for patients who 
received a sutured scaffold) [37].  
Single-step scaffold-based treatment + MFx vs. (M)ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on “necessity of a total joint re-
placement”, compared to (M)ACI.  
 
Function 
D0016 – How does the use of the technology affect  
activities of daily living? 
Answering this research question was based on the outcome “return to activ-
ities”. 
Single-step scaffold-based treatment + MFx vs. MFx 
This outcome was not reported in any of the identified studies comparing the 
single-step scaffold-based treatment with MFx. 
Single-step scaffold-based treatment + MFx vs. (M)ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on “return to activities”, com-
pared to (M)ACI.  
 
Health-related quality of life 
D0012 – What is the effect of the technology  
on generic health-related quality of life? 
Single-step scaffold-based treatment + MFx vs. MFx 
The generic quality of life was measured in one RCT (with initially 80 pa-
tients) using the mental components of the SF-36 (version 2)8. After 12 months, 
the score improved by 13 points in the treatment group and by ca. 14.8 points 
in the control group. After 60 months (compared to baseline), the score im-
proved by 13.1 points in the treatment group and by 14.5 points in the con-
trol group. The differences in changes of the scores between the study groups 
were statistically not significant at both time points [36, 38]. 
Single-step scaffold-based treatment + MFx vs. (M)ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on generic health-related qual-
ity of life, compared to (M)ACI.  
                                                             
8 The Short-Form Health Survey (SF-36) version 2 is an eight-scale profile of function-
al health and well-being scores plus summary components of physical and mental 
health. 
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D0013 – What is the effect of the technology  
on disease-specific quality of life? 
Single-step scaffold-based treatment vs. MFx 
The disease-specific quality of life was measured in one RCT (with initially 
80 patients) using the physical component of the SF-36 (version 2)8. After 12 
months, the score increased by 3.5 points in the treatment group and by ca. 0.8 
points in the control group. After 60 months (compared to baseline), the score 
increased by 2.7 points in the treatment group and decreased by nearly 0.2 
points in the control group. The difference in changes of the score between 
the study groups was statistically not significant at either time points [36, 38]. 
Additionally, since (osteo)chondral defects can cause pain, resulting in a low 
quality of life, the results of the treatments on pain are presented as well. Pain 
was measured in all of the included studies, however, the methods of meas-
urement differed. 
In one RCT, pain was measured on a visual analogue scale (scale: 0-100). The 
score for pain decreased (improved) over time in both treatment groups. After 
12 months, the score improved by 32 points in the treatment and the control 
group, respectively. After 24 months (compared to baseline), the score im-
proved by 37 points in the treatment group and by 38 points in the control 
group. The difference in changes of the scores between the study groups was 
statistically not significant at either time points [37]. 
In the other identified RCT, pain was measured with the WOMAC9 subscale 
score for pain (scale: 0-50). After 12 months, the score improved by 16.2 points 
in the treatment group and by ca. 16.9 points in the control group. After 60 
months (compared to baseline), the score improved by 15.4 points in the treat-
ment group and by 16.6 points in the control group. The difference in chang-
es of the scores between the study groups was statistically not significant at 
either time points [36, 38]. 
In the identified non-randomised CT, the severity and frequency of pain was 
measured. However, it was not stated on which scale or scoring system the 
measurement was based on. After six months, the score for the severity of pain 
improved by 32.1 points in the treatment group and by 15.3 points in the 
control group. The score for the frequency of pain improved after 6 months 
of follow-up by 52.9 points in the treatment group and by 41 points in the 
control group. It was not stated whether the differences between study groups 
in changes were statistically significant or not [39]. 
Single-step scaffold-based treatment + MFx vs. (M)ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on disease-specific quality of 
life, compared to (M)ACI.  
 
                                                             
9 The WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) 
scoring system includes pain, stiffness and physical function, measured on a visual 
analogue scale (VAS).  
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Procedure-related complications 
 Device-related complications 
 Re-operations rate 
Procedure-related adverse events are complications that are associated with 
the surgical intervention. Possible procedure-related complications are events 
associated with anaesthesia, infections, damages to nerves or blood vessels, 
bleeding, or the occurrence of blood clots (e.g. thrombosis). 
Device-related complications are adverse event associated with the implan-
tation of the scaffold. Possible complications are, e.g. movement or release of 
the scaffold or allergic reactions.  
The re-operation rate shows how often patients had to undergo additional sur-
geries. It was chosen as an indicator for (major) adverse events. 
 
 
6.2 Included Studies 
For evaluating safety-related outcomes, we considered RCTs, prospective non-
randomised controlled trials, and prospective single-arm studies, the latter 
only in case they included at least 50 patients and had a follow-up of at least 
24 months (see Chapter 1.2).  
We could not identify any clinical trials comparing the single-step scaffold-
assisted treatment of chondral defects in the knee with (M)ACI.  
The only studies that met our inclusion criteria were two RCTs10 [36-38] and 
one non-randomised CT [39] with a total of 136 patients, assessing the safety 
of the single-step scaffold-assisted cartilage repair in the knee. Of the 136 pa-
tients, 84 received single-step scaffold-supported intervention and the remain-
ing 52 were in the control groups. 
The included controlled trials compared the single-step scaffold-assisted chon-
dral repair in the knee joint (scaffold-groups) in combination with microfrac-
turing (MFx) [36-39], compared to MFx alone (MFx-groups) [36-39]. 
The mean age of patients ranged from 33 to 38 years in the treatment groups 
and from 37 to 41 years in the control groups across trials. Between 15 and 
44% of the patients in the scaffold-groups and 20-36% of the patients in the 
control groups were females across trials. Patients had grade 3 to 4 (Outer-
bridge Classification) of chondral defects. The follow-up of the studies was 6, 
24 and up to 60 months (5 years) [36-39]. 
                                                             
10 Data from 2 publications of one study population, presenting results after 1 year 
and results after 5 years follow-up, are presented together. 
entscheidende 
Endpunkte für 
Sicherheit 
eingriffsbezogene 
Komplikationen 
implantatbezogene 
Komplikationen 
Reoperationsrate 
(un)kontrollierte 
Studien für Sicherheit 
keine Studien im 
Vergleich zu (M)ACI 
3 Studien mit 136 
PatientInnen 
Studien zu chondralen 
Läsionen im Kniegelenk 
PatientInnen:  
Ø 33-38 vs. 37-41 Jahre, 
15-44 vs. 20-36 % Frauen, 
Stadium 3-4, 
Nachbetrachtungszeit 
6-60 Monate 
Single-step scaffold-based cartilage repair in the knee 
38 LBI-HTA | 2016 
In one study, it was Chondro-Gide® [37], in another, BST-CarGel® [36, 38], 
and in the third study, a polyethylene glycol diacylate hydrogel (comparable 
to GelrinC®) that were applied [39].  
There were no studies assessing the clinical effectiveness of other products, 
like CaReS®-1S, Chondrotissue®, MaioregenTM or MeRG® (see Chapter 3) that 
met our inclusion criteria. 
Study characteristics and results of included studies are displayed in Table 
A-1 and in the evidence profile in Table 7-1. 
 
 
6.3 Results 
Patient safety 
C0008 – How safe is the technology in comparison to the comparator(s)? 
Single-step scaffold-based treatment + MFx vs. MFx 
Adverse events – that were related to the surgical procedure, in comparison to 
MFx – were reported in two RCTs [36-38] and in one non-randomised CT 
[39]. The reported rates ranged from 0 to 93% in the scaffold-groups and from 
0 to 77% in the MFx-groups [36-39]. 
Adverse events – that were related to the scaffold – occurred in 0-22% of the 
patients (reported in two RCTs) [36-38]. Since the control groups did not re-
ceive a scaffold, no scaffold-related complications occurred. 
In none of the identified studies it was clearly stated which kind of adverse 
events occurred. In one study, it was stated that one patient in the treatment 
group had mild haemarthrosis [39]. In another study, it was stated in general 
terms that the most frequent adverse were arthralgia, pain, and nausea in the 
treatment group, and arthralgia and pain in the control group [36, 38]. 
Moreover, in none of the identified studies it was stated if any re-operations 
were necessary.  
Single-step scaffold-based treatment + MFx vs. (M)ACI 
There was no evidence available assessing the safety of a single-step scaffold-
assisted cartilage repair (combined with MFx), compared to (M)ACI.  
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
Based on the identified evidence, this research question cannot be answered 
in an appropriate way. 
C0005 – What are the susceptible patient groups  
that are more likely to be harmed through the use of the technology? 
No direct evidence was found to answer this research question.  
C0007 – Are the technology and comparator(s) associated  
with user-dependent harms? 
No direct evidence was found to answer this research question.  
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7 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) scheme [2] for each 
endpoint, individually. Each study was rated by two independent research-
ers. In case of disagreement a third researcher was involved to solve the dif-
ference. A more detailed list of criteria applied can be found in the recom-
mendations of the GRADE Working Group [2].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close  
to that of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate:  
the true effect is likely to be close to the estimate of the effect,  
but there is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or  
does not permit a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1.  
Overall, the strength of evidence evaluating the effectiveness and safety of 
single-step scaffold-based cartilage repair of the knee in combination with 
microfracturing compared to microfracturing alone is “low”. 
Exceptions are the results from one RCT [36, 38] regarding the measurement 
of joint functionality and pain (measured with the WOMAC subscale scores 
for function, stiffness and pain). Even though the patient number of this RCT 
was small, the standard deviations of these outcomes were low and baseline 
values between the study groups were similar. Another exception is the out-
come “necessity of total joint replacement”, reported in another RCT [37]. 
The strength of evidence of these outcomes was rated as “moderate”. 
For the comparison to (matrix-assisted) autologous chondrocyte implantation 
no evidence was available.  
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Table 7-1: Evidence profile: efficacy and safety of single-step cartilage repair of knee joints  
with a scaffold in combination with microfracturing in comparison to microfracturing alone (results of controlled trials) 
No of 
studies/
patients 
Study 
Design Estimate of effect Study limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength  
of evidence 
Efficacy 
Mobility/joint functionality: change from baseline (IKDC Score: 0-100) 
1/18 
1/18 
CT 
CT 
3 mo: n/a; p=N.S. 
6 mo: n/a; p=N.S 
Serious limitations (-1)11 
Serious limitations (-1)11 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)12 
Imprecise data (-1)12 
Very low 
Very low 
Mobility/joint functionality: change from baseline (Modified ICRS Score) 
1/30 
1/27 
RCT 
RCT 
12 mo: n/a; p=N.S. 
24 mo: n/a; p=N.S. 
Serious limitations (-1)13 
Serious limitations (-1)13 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)12 
Imprecise data (-1)12 
Low 
Low 
Mobility/joint functionality: change from baseline (Modified Cincinnati Score: 6-100) 
1/30 
1/27 
RCT 
RCT 
12 mo14: +35 (±29)/+19 (±22) vs. +31 (±13); p=N.S. 
24 mo14: +46 (±17)/+37 (±14) vs. +44 (±15); p=N.S. 
Serious limitations (-1)15 
Serious limitations (-1)15 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)12 
Imprecise data (-1)12 
Low 
Low 
Mobility/joint functionality: change from baseline (WOMAC subscale score for stiffeness: 0-20) 
1/78 
1/59 
RCT 
RCT 
12 mo: -5.97 (±0.68) vs. -6.56 (±0.71); p=N.S. 
60 mo: -5.63 (±0.72) vs. -6.68 (±0.58); p=N.S. 
Serious limitations (-1)16 
Serious limitations (-1)17 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
None 
None 
Moderate 
Moderate 
Mobility/joint functionality: change from baseline (WOMAC subscale score for function: 0-170) 
1/78 
1/59 
RCT 
RCT 
12 mo: -55.96 (±4.24) vs. -60.59 (±4.41); p=N.S. 
60 mo: -56.52 (±4.57) vs. -62.10 (±3.43); p=N.S. 
Serious limitations (-1)16 
Serious limitations (-1)17 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
None 
None 
Moderate 
Moderate 
                                                             
11 High risk of bias due to likely confounding (patient’s baseline characteristics not comprehensively provided or controlled for), selection of participants (study protocol  
was switched from “randomised” to “non-randomised”, unclear consecutively patients’ recruiting) and outcome measurement (subjective measurement, patients + personnel 
were aware of intervention). 
12 Low incidence/patient numbers. 
13 High risk of bias due to likely selective outcome reporting (unclear approach for assessing Modified ICRS + values not stated, not study protocol),  
no blinding (patients + personnel were aware of intervention) and other aspects (study is interim analysis, no adherence of possible effects of physiotherapy or pain killers). 
14 Two treatment modalities were used in the scaffold-arm: one group received a sutured and the other group received a glued scaffold. 
15 High risk of bias due to no blinding (patients + personnel were aware of intervention) and other aspects  
(study is interim analysis, no adherence of possible effects of physiotherapy or pain killers). 
16 High risk of bias due to unclear allocation concealment, no blinding (patients + personnel were aware of intervention) and other aspects  
(no adherence of possible effects of physiotherapy or pain killers). 
17 High risk of bias due to unclear allocation concealment, no blinding (patients + personnel were aware of intervention) and other aspects  
(no adherence of possible effects of physiotherapy or pain killers + post-hoc extension). 
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1 
No of 
studies/
patients 
Study 
Design Estimate of effect Study limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength  
of evidence 
Quality of life: change from baseline (SF-36 physical component) 
1/78 
1/59 
RCT 
RCT 
12 mo: +13.02 (±1.5) vs. +14.76 (±1.52); p=N.S. 
60 mo: +13.12 (±1.63) vs. +14.48 (±1.42); p=N.S. 
Serious limitations (-1)16 
Serious limitations (-1)18 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)19 
Imprecise data (-1)19 
Low 
Low 
Quality of life: change from baseline (SF-36 mental component) 
1/78 
1/59 
RCT 
RCT 
12 mo: +3.54 (±1.56) vs. +0.84 (±1.58); p=N.S. 
60 mo: +2.72 (±1.3) vs. -0.17 (±1.76); p=N.S. 
Serious limitations (-1)16 
Serious limitations (-1)18 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)19 
Imprecise data (-1)19 
Low 
Low 
Pain: change from baseline (VAS: 0-100) 
1/30 
1/27 
RCT 
RCT 
12 mo14: -32 (±n/a)/-32 (±n/a) vs. -35 (±n/a); p=N.S. 
24 mo14: -37 (±n/a)/-38 (±n/a) vs. -49 (±n/a); p=N.S. 
Serious limitations (-1)20 
Serious limitations (-1)20 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)12 
Imprecise data (-1)12 
Low 
Low 
Pain: change from baseline (WOMAC subscale score for pain: 0-50) 
1/78 
1/59 
RCT 
RCT 
12 mo: -16.16 (±1.16) vs. -16.91 (±1.21); p=N.S. 
60 mo: -15.37 (±1.47) vs. -16.56 (±1.19); p=N.S. 
Serious limitations (-1)16 
Serious limitations (-1)17 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
None 
None 
Moderate 
Moderate 
Pain: change from baseline (severity) 
1/18 
1/18 
CT 
CT 
3 mo:: -29 (±n/a) vs. -34.7 (±n/a); p=n/a 
6 mo:: -32.1 (±n/a) vs. -15.3 (±n/a); p=n/a 
Serious limitations (-1)21  
Serious limitations (-1)21  
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)12 
Imprecise data (-1)12 
Very low 
Very low 
Pain: change from baseline (frequency) 
1/18 
1/18 
CT 
CT 
3 mo:: -41 (±n/a) vs. -62.6 (±n/a); p=n/a 
6 mo:: -52.9 (±n/a) vs. -41 (±n/a); p=n/a 
Serious limitations (-1)21 
Serious limitations (-1)21 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)12 
Imprecise data (-1)12 
Very low 
Very low 
Necessity of total joint replacement (in % of patients) 
1/27 RCT14 24 mo: 0/8 vs. 0; p=n/a No serious limitations22 n/a (only 1 trial) Direct Imprecise data (-1)12 Moderate 
                                                             
18 High risk of bias due to unclear allocation concealment, no blinding (patients + personnel were aware of intervention) and other aspects (no adherence of possible effects  
of physiotherapy or pain killers + post-hoc extension). It is not clear how many patients were exactly included in analysis for quality of life. 
19 High margin of deviation, no baseline values stated. 
20 High risk of bias due to no blinding (patients + personnel were aware of intervention) and other aspects (study is interim analysis, no adherence of possible effects of physiotherapy 
or pain killers). Furthermore, values for dispersion / variability were not stated. 
21 High risk of bias due to likely confounding (patient’s baseline characteristics not comprehensively provided or controlled for), selection of participants (study protocol was 
switched from “randomised” to “non-randomised”, unclear consecutively patients’ recruiting) and outcome measurement (subjective measurement, patients + personnel were 
aware of intervention). Furthermore, values for dispersion / variability were not stated and it was not stated if study-group-difference was statistically significant or not. 
22 Potentially, risk of bias due to missing study protocol and the fact that study is interim analysis. However, risk of bias was classified as low. 
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No of 
studies/
patients 
Study 
Design Estimate of effect Study limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength  
of evidence 
Safety 
Procedure-related complications (in % of patients) 
1/18 
1/78 
1/38 
1/60 
CT 
RCT 
RCT 
RCT 
6 mo: 7 vs. 0 
12 mo: 93 vs. 77; p=n/a 
24 mo: 0 vs. 0 
60 mo: 6 vs. 8; p=n/a 
Serious limitations (-1)23 
Serious limitations (-1)24 
Serious limitations (-1)25 
Serious limitations (-1)26  
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Direct 
Direct 
Imprecise data (-1)12 
Imprecise data (-1)12 
Imprecise data (-1)12 
Imprecise data (-1)12 
Very low 
Low 
Low 
Low 
Device-related complications (in % of patients) 
1/78 
1/38 
1/60 
RCT 
RCT 
RCT 
12 mo: 22 vs. - 
24 mo: 0 vs. - 
60 mo: 3 vs. - 
No serious limitations27 
Serious limitations (-1)28 
Serious limitations (-1)29 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Direct 
Imprecise data (-1)12 
Imprecise data (-1)12 
Imprecise data (-1)12 
Moderate 
Low 
Low 
Re-operation rate (in % of patients): no evidence 
Abbreviations: CT = (non-randomised) controlled trial; ICRS = International Cartilage Repair Society; IKDC = International Knee Documentation Committee; mo = month(s);  
n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; SF-36 = Short-Form Health Survey; S.S. = statistically significant; vs. = versus;  
WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: n/a: not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
                                                             
23 High risk of bias due to likely confounding (patient’s baseline characteristics not comprehensively provided or controlled for), selection of participants (study protocol was 
switched from “randomised” to “non-randomised”, unclear consecutively patients’ recruiting) and outcome measurement (patients + personnel were aware of intervention).  
Furthermore, it seems likely that procedure-related complications were not reported comprehensively and the definition of “procedure-related” complications was not stated. 
24 High risk of bias due to no blinding (patients + personnel were aware of intervention). Furthermore, it was not stated if study-group-difference was statistically significant or 
not. Furthermore, the definition of “procedure-related” complications was not stated. 
25 High risk of bias due to no blinding (patients + personnel were aware of intervention) and other aspects (study is interim analysis). Furthermore, it seems likely that  
procedure-related complications were not reported comprehensively and the definition of “procedure-related” complications was not stated. 
26 High risk of bias due no blinding (patients + personnel were aware of intervention) and other aspects (study is an extension). Furthermore, the definition of “procedure-related” 
complications was not stated. 
27 Potentially, risk of bias since the definition of “device-related” complications was not stated. However, risk of bias was classified as low. 
28 High risk of bias due to the fact, that study is interim analysis. Furthermore, it seems likely that device-related complications were not reported comprehensively and the  
definition of “device-related” complications was not stated. 
29 High risk of bias due to the fact, that study is an extension. Furthermore, the definition of “device-related” complications was not stated. 
 LBI-HTA | 2016 43 
8 Discussion 
Chondral or osteochondral lesions are difficult-to-treat entities that often af-
fect young and active persons. Moreover, cartilage has limited intrinsic heal-
ing potential due to the fact that it is isolated from the systemic regulation and 
lacks vessels plus nerve supply, which contributed to the fact that cartilage 
healing remains challenging. 
Chondral and osteochondral defects severely reduce the quality of life of the 
affected persons, especially due to the associated pain. Untreated or progress-
ing defects can lead to osteoarthrosis and to the necessity to replace the affect-
ed joint in the long run. 
The aim of this report was to assess the clinical effectiveness and safety of the 
single-step matrix-assisted cartilage repair in the knee joint (combined with 
microfracturing), compared to MFx alone or (M)ACI. 
For assessing the clinical effectiveness and safety of the single-step matrix-as-
sisted cartilage repair in the knee joint (combined with microfracturing) com-
pared to MFx alone, we identified three clinical trials (two randomised trials 
and one non-randomised study) involving 168 patients that met our inclusion 
criteria.  
All trials used different products of scaffolds: Chondro-Gide® and BST-CarGel®. 
Furthermore in one trial, a polyethylene glycol diacrylate hydrogel was used. 
Due to the same components, it is possible that the used product was Gel-
rinC®. All of the identified studies included patients with chondral defects in 
the knee. 
The mean defect sizes were slightly larger in the intervention groups com-
pared to the control groups (2.3-3.7 vs. 2-2-9 cm²). None of the studies in-
cluded exclusively patients with defect sizes larger than 2.5 cm². However, 
the comparison to MFx alone would have not been ideal. 
The scores measuring the mobility or joint functionality and pain (reported 
in all three controlled trials) plus quality of life (measured in only one study) 
improved in the groups that received the single-step scaffold-assisted treat-
ment (+ MFx) as well as in the groups that received MFx alone in a compa-
rable extent. The differences of the improvements between the study groups 
were not significant in any of the studies [36-39].  
Complications were reported in all extracted studies. However, the compli-
cation rates between the studies differed considerably, keeping in mind that 
different follow-up periods might have contributed to this observation. Pro-
cedure-related adverse events occurred in 0-93% of the patients in the scaf-
fold-groups (0-77% in the control groups) across studies. The rates for device-
related complications differed from 0 to 22% across studies [36-39]. 
The clinical results are consistent in their suggestion that the single-step scaf-
fold-assisted cartilage repair in combination with MFx leads to similar short 
to medium-term (up to five years follow-up) results, compared to MFx alone. 
However, the overall strength of evidence for clinical effectiveness and safety 
was determined as “low”. For the identified non-randomised CT this is due to 
the study design: the strength of evidence of observational studies generally 
starts with “low”. The strength of evidence of identified RCTs was mainly 
downgraded due to the fact that the outcomes were subjective and the patients 
as well as the assessing personnel were aware of the intervention. 
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A major issue of the identified trials is the low number of patients of each 
study. One RCT consisted of 80 patients, whereas the smallest controlled tri-
al included only 18 patients. Especially for identifying rare (unanticipated) 
complications, these patient numbers might be insufficient. Small numbers 
are furthermore likely to have impacted the trials’ ability to detect between-
group differences in efficacy outcomes. 
Two of the studies had a relatively short follow-up of one year or less. Only 
one of the studies had a follow-up of at least five years. Therefore, reliable data 
of long-term efficacy and safety-related outcomes are missing. 
The applied interventions differed slightly between the individual studies. 
First of all, in one study, the scaffold was a hydrogel and in the other studies 
it was a kind of “fleece”. Another potential effect on the outcomes could be 
the fixation-technique of the scaffold (e.g. if it was glued or sutured). Fur-
thermore, the MFx-procedure in the control groups was either performed ar-
throscopically or by miniarthrotomy.  
One outcome that was defined as crucial – necessity of a total joint replace-
ment – was exclusively reported in only one trial (whereas one patient in the 
scaffold-group required a new joint). However, this outcome is important to 
assess the long-term efficacy of the treatment of chondral or osteochondral de-
fects. It is however acknowledged that for meaningful prospective data to be 
collected on joint replacement rates, a very long follow-up and/or large sam-
ples might be necessary. 
Due to the incomprehensive or inconsistent screening, recording and/or re-
porting of adverse events across the majority of included studies, aggregated 
statements on the safety are barely possible. This was deemed an important 
shortcoming for the majority of included studies. In one RCT, it seems that 
adverse events were recorded systematically, resulting in a procedure-related 
complications rate of ca. 93% in the treatment group. In another RCT, the 
rates of procedure-related complications were only reported as 0%. This dis-
crepancy hints at different approaches to safety. It has to be stated that due 
to the invasive nature of the interventions compared, an AE rate close to 0% 
could be questioned. Furthermore, in none of the studies was it clearly stat-
ed and sufficiently explained which adverse events occurred.  
Not all studies conclusively reported additional interventions (e.g. meniscec-
tomies, etc.) during or before the initial surgery. However, it is possible that 
additional procedures have had an impact on the outcomes. 
Moreover, it was barely reported if patients received additional medication 
after the surgical procedure or even in the long run, e.g. for symptom control. 
It is evident that e.g. the intake of painkillers at the time of follow-up could 
have impacted outcome assessment, like pain and quality of life. 
One of the identified studies [39] was initially conducted as an RCT. How-
ever, the randomisation was stopped after only three patients were assigned 
to the control group. This study was treated as non-randomised CT in our 
report. Alternatively, it could have been considered as a case-series since the 
change in protocol during the trial had the subsequent patients recruited ex-
clusively to the scaffold arm to enlarge the safety database. 
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There is no robust evidence that the single-step scaffold-assisted cartilage re-
pair combined with microfracturing leads to better outcomes than MFx alone. 
From the extracted evidence, it appears that the intervention is not superior 
compared to MFx, at best equal. Long-term data are lacking. Furthermore, 
there is a need for safety trials that focus on rare adverse events. 
For assessing the clinical effectiveness and safety of the single-step matrix-
assisted cartilage repair in the knee joint (combined with microfracturing) 
compared to (M)ACI, we could not identify any studies that met our inclu-
sion criteria. 
Nevertheless, several systematic reviews have shown that there is no sufficient 
evidence to conclude whether ACI or MACI is superior to other treatment 
strategies for treating cartilage defects (in the knee). It appears that the (M)ACI 
procedure is relatively safe and that it is not associated with serious adverse 
events. However, patients need to be aware that as the (M)ACI procedure in-
volves two operations, it may be associated with a higher rate of adverse events 
than other treatments [40-42]. 
In the short to medium-term, the effectiveness of (M)ACI in terms of func-
tional, pain, and quality of life outcomes appears to be comparable to micro-
fracturing, mosaicplasty, conservative treatments, or osteochondral allograft 
[40-42]. 
In 2009, the Federal Joint Committee (Gemeinsamer Bundesausschuss; G-BA) 
in Germany concluded that MACI (ACI was not in the focus of that assess-
ment) is a promising intervention. However, the evidence was not sufficient 
to demonstrate a clinical benefit and therefore, the intervention should be 
re-evaluated (the re-evaluation was planned for 2014, but no results are pub-
lished yet) [43]. 
Naturally, our systematic review has several weaknesses too: 
First of all, we decided to include case-series exclusively for assessing the safe-
ty and therefore we just considered larger case series with a longer follow-up. 
Thus, we excluded case series with less than 50 patients or a follow-up of less 
than 2 years. Presumably then, there were studies with less than 50 patients 
with a longer follow-up or studies with more patients and a shorter follow-up. 
Therefore, it is possible that we excluded studies that reported results of e.g. 
other products or complications.  
Moreover, we excluded all studies in which the single-step matrix-assisted car-
tilage repair was not exclusively performed in combination with microfrac-
turing. Due to this reason, we excluded one non-randomised controlled trial 
(patients in the control groups received MACI) and two single-arm studies. 
Furthermore, we excluded retrospective studies – even controlled studies with 
a retrospective control group – because the sources of error due to confound-
ing and bias are more common in retrospective studies than in prospective 
ones. 
It might be that we did not identify all appropriate studies, although we used 
different terms in the systematic literature search, asked the manufacturers 
for studies and supplemented our search by a handsearch and an additional 
search in Scopus. This is mainly due to the inconsistent wording for the as-
sessed technology of cartilage repair. Thus, we identified a large part of the 
studies by handsearch. In addition, it is possible that we did not identify all 
manufacturers asking for studies. 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and the according 
choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to conclude that the single-step matrix-
assisted cartilage repair (combined with microfracturing) is more effective and 
safer than microfracturing or as effective, but safer than (matrix-assisted) au-
tologous chondrocyte implantation. 
New study results, especially from studies with larger patient numbers and 
longer follow-up (e.g. ten years), will potentially influence the effect estimate 
considerably. 
A re-evaluation is recommended not before 2018, since the technique seems 
to be promising and there are still ongoing studies (see Appendix). At the mo-
ment, it seems too early to include the single-step scaffold-assisted cartilage 
repair of the knee in the catalogue of benefits. 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Single-step cartilage repair of knee joints with a scaffold in combination with microfracturing: Results from controlled trials 
Author, year Anders 2013 [37] Sharma 2013 [39] Shive 2014 [36] (Stanish 2013 [38]) 
Country Germany Germany, Italy, Netherlands Canada, Spain, South Korea 
Sponsor n/a30 Arthritis Foundation, NIH BioSyntech Canada Inc., Piramal Life Sciences 
Intervention/Product Arthroscopy+miniarthrotomy, single-step 
cartilage repair31 + MFx/Chondro-Gide® 
Miniarthrotomy, single-step cartilage repair + 
MFx/n/a32 
Arthroscopy+miniarthrotomy, single-step 
cartilage repair + MFx/BST-CarGel® 
Comparator Arthroscopic MFx alone Miniarthrotomic MFx alone Arthroscopic MFx alone 
Study design RCT CT33 RCT34 
Number of pts. 28 (13/15)35 vs. 10 15 vs. 3 41 vs. 39 
Lesion Cartilage defect of knee Medial femoral condyle defect (knee) Femoral condyle cartilage lesion (knee) 
Inclusion criteria Pts. with isolated cartilage defects (2-10 cm²) in 
the knee, Grade 3-4 Outerbridge Classification, 
aged 21-50 yrs. 
Pts. aged 18 - 50 years, standing radiograph showing a 
Kellgren score of 0–2, diagnostic arthroscopy/MRI 
identification of a medial femoral condyle defect, 
stable and asymptomatic contralateral knee 
Pts. with a single, focal cartilage lesion in the 
knee and moderate pain, aged 18-55 yrs. 
                                                             
30 It is not clear, who sponsored the study. However, it is stated that the authors acknowledge Geistlich Pharma for the support. 
31 Patients in the treatment group were divided, whether the scaffold was sutured or glued into the affected area. Thus, two treatment groups exist. 
32 A polyethylene glycol diacrylate hydrogel was used as scaffold (like GelrinC). 
33 Study was initiated as a RCT, however, randomisation was stopped during the study to increase the size of the hydrogel cohort. 
34 Study results after 1 year were published in Stanish 2013 (assessing 41 vs. 39 pts.) and results after 5 years follow-up were presented in Shive 2014 (assessing 34 vs. 26 pts.).  
Therefore, data from both publications are presented together. However, the initial study protocol was planned for 12 months follow-up only. 67 of the 80 intial pts. were enrolled 
in the extension study. 
35 In 13 patients the scaffold was sutured and in 15 patients the scaffold was glued. 
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Author, year Anders 2013 [37] Sharma 2013 [39] Shive 2014 [36] (Stanish 2013 [38]) 
Exclusion criteria Pts. with: >2 defetcs, 2 corresponding defets, 
defects on both knees, sign of ostoarthrosis, 
bone lesion >0.7 cm, uncorrected knee 
instability. Rheumatoid arthritis, 
(para)infectious diseases, chronic heart, 
endocrine, metabolic or autoimmune diseases, 
varus or valgus deformation, previous complete 
meniscus resection, mosaicplasty, treatment 
with cartilage specific medication, 
chondropathia patellae or dysplasia of patella 
Alcohol or drug abuse, passive motion deficit of the knee 
(>5° of extension, >15° of flexion), osteoarthritis, 
rheumatoid arthritis or gout, pregnant or nursing 
mothers, active inflammatory disease, such as lupus, 
history of severe allergy (as defined by a reaction which 
required treatment such as injection with epinephrine), 
atopic disease, or known allergy to bovine proteins, 
evidence of significant haematological disorder (severe 
preexisting coagulation disorder requiring active 
coagulation therapy), cardiovascular, liver, or neoplastic 
disease, bone malignancy, autoimmune disorders, or 
kidney disease, recent history (less than 4 weeks) of 
myocardial infarction or concurrent acute injury that 
might compromise the subject’s welfare, diabetes 
mellitus, life expectancy of less than 5 years, untreated 
depression, chronic steroid intake, patellofemoral 
instability, malalignment with >5° valgus or varus 
compared to normal, prior cartilage surgery of the 
affected knee (e.g. subchondral drilling, microfracture, 
abrasion arthroplasty, mosaicplasty, autologous 
chondrocyte implantation) 
Pts. with multiple lesions or kissing lesions, 
clinically relevant compartment malalignment 
(> 5 degrees), pts who underwent ligament 
treatments in the affected knee within 2 years 
prior to trial, inflammatory arthropathy, such 
as rheumatoid arthritis, systemic lupus, or 
active gout, previous surgical cartilage 
treatments in the affected knee in the last 12 
months 
Prior surgery, n (%) 8 (62)/8 (53) vs. 5 (50) None (exclusion criterion) n/a36 
Postoperative 
treatment(s) 
Physiotherapy/rehabilitation (all pts.) Physiotherapy/rehabilitation (all pts.) Physiotherapy/rehabilitation (all pts.) 
Age of patients (yrs.)  Ø 33/38 vs. 41; p=n/a 20-59 vs. 40-4937; p=n/a Ø 35 vs. 37, p=N.S. 
Sex (% female) 15/20 vs. 20; p=n/a n/a 44 vs. 36; p=n/a 
BMI (kg/m²) Ø 27.8/27.7 vs. 24.6; p=n/a 20-30+ vs. 20-3037; p=n/a Ø 27.0 vs. 25.2; p=N.S. 
Defect size (cm²) Ø 3.7/3.5 vs. 2.9; p=n/a 1-3 vs. 2-337; p=n/a Ø 2.32 vs. 1.95; p=N.S. 
Clinical classification  
(% pts) 
Grade 3 (Outerbridge): 54/40 vs. 40; p=n/a 
Grade 4 (Outerbridge): 46/60 vs. 60; p=n/a 
n/a n/a 
Primary endpoint(s) n/a n/a Degree of lesion fill & repair cartilage T2 
relaxation time (both via MRI) 
Follow-up (months) 24 6 60 
Loss to follow-up, n (%) 12 months: 4 (31)/2 (13) vs. 2 (20); p=n/a 
24 months: 5 (38)/2 (13) vs. 4 (40); p=n/a 
0 vs. 0 12 months: 0 vs. 2 (5); p=n/a 
60 months: 8 (20) vs. 13 (33)38; p=n/a 
                                                             
36 There was no prior surgery in the last 12 months before the start of the study. 
37 Values were only given as ranges and not as means or medians (or exact numbers). 
38 Loss to follow-up for assessing joint functionality by WOMAC score. 
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Author, year Anders 2013 [37] Sharma 2013 [39] Shive 2014 [36] (Stanish 2013 [38]) 
Effectiveness39 
Mobility/joint 
functionality 
Modified Cincinnati Score (6-100) 40: 
Baseline: ø 47 (±20)/47 (±15)  
vs. 37 (±14)41; p=n/a 
Change after 3; 6 months: n/a 
Change after 12 months: ø +35 (±29)/+19 (±22) 
vs. +31 (±13); p=N.S. 
Change after 24 months: ø +46 (±17)/+37 (±14) 
vs. +44 (±15); p=N.S. 
Change after 36; 48; 60 months: n/a 
Modified ICRS Score42: 
Baseline: n/a 
Change after 3; 6 months: n/a 
Change after 12 months: n/a; p=N.S. 
Change after 24 months: n/a; p=N.S. 
Change after 36; 48; 60 months: n/a 
IKDC Score (0-100) 43: 
Baseline: n/a, p=N.S. 
Change after 3 months: n/a; p=N.S. 
Change after 6 months: n/a; p=N.S. 
Change after 12; 24; 36; 48; 60 months: n/a 
WOMAC subscale score stiffness (0-20) 44: 
Baseline: ø 10.5 (±4.4) vs. 9.4 (±4.9); p=N.S. 
Change after 3; 6 months: n/a 
Change after 12 months: ø -5.97 (±0.68)  
vs. -6.56 (±0.71); p=N.S. 
Change after 24; 36, 48 months: n/a 
Change after 60 months: ø -5.63 (±0.72)  
vs. -6.68 (±0.58); p=N.S. 
WOMAC subscale score function (0-170) 44: 
Baseline: ø 80.3 (±38.5) vs. 75.9 (±38); p=N.S. 
Change after 3; 6 months: n/a 
Change after 12 months: ø -55.96 (±4.24)  
vs. -60.59 (±4.41); p=N.S. 
Change after 24; 36, 48 months: n/a 
Change after 60 months: ø -56.52 (±4.57)  
vs. -62.10 (±3.43); p=N.S. 
Return to activities n/a n/a n/a 
                                                             
39 Reported p-values pertain to between-arm comparisons. 
40 The Modified Cincinnati Score is divided into 3 parts: knee function (6-30 points), clinical pathology (0-20 points), highest activity level without pain (0-50 points). 
41 Baseline values are based on whole study sample, whereas changes from baseline are calculated based on the sample that remained at follow-up, only. 
42 The Modified ICRS (International Cartilage Repair Society) Score consists of ratings by patient (pain, functional status of knee) and surgeon (functional status knee,  
classification + crepitation). 
43 The IKDC (International Knee Documentation Committee) scoring system includes 10 items investigating symptoms, function and return to sporting activities. 
44 The WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scoring system includes pain, stiffness and physical function, measured on a visual  
analogue scale (VAS). Only the subscale scores for stiffness, function and pain were presented. 
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Author, year Anders 2013 [37] Sharma 2013 [39] Shive 2014 [36] (Stanish 2013 [38]) 
Quality of life n/a n/a SF-36 v2 physical component 45: 
Baseline: n/a 
Change after 3; 6 months: n/a 
Change after 12 months: ø +13.02 (±1.5)  
vs. +14.76 (±1.52); p=N.S. 
Change after 24; 36, 48 months:n/a 
Change after 60 months: ø +13.12 (±1.63)  
vs. +14.48 (±1.42); p=N.S 
SF-36 v2 mental component 45:  
Baseline: n/a 
Change after 3; 6 months: n/a 
Change after 12 months: ø +3.54 (±1.56)  
vs. +0.84 (±1.58); p=N.S. 
Change after 24; 36, 48 months:n/a 
Change after 60 months: ø +2.72 (±1.3) vs. -
0.17 (±1.76); p=N.S 
Pain VAS (0-100)46: 
Baseline: ø 46/48 vs. 54; p=n/a 
Change after 3; 6 months: n/a 
Change after 12 months: ø -32 (±n/a)/-32 (±n/a) 
vs. -35(±n/a); p=N.S. 
Change after 24 months: ø -37 (±n/a)/-38 (±n/a) 
vs. -49 (±n/a); p=N.S. 
Change after 36; 48; 60 months: n/a 
Severity47: 
Baseline ø 54.3 (±16.4) vs. 54 (±21); p=n/a. 
Change after 3 months: ø -29 (±n/a)  
vs. -34.7 (±n/a); p=n/a 
Change after 6 months: ø -32.1 (±n/a)  
vs. -15.3 (±n/a); p=n/a 
Change after 12; 24; 36; 48; 60 months: n/a 
Frequency47: 
Baseline: ø 77 (±20.3) vs. 84.3 (±24.5); p=n/a. 
Change after 3 months: ø -41 (±n/a)  
vs. -62.6 (±n/a); p=n/a 
Change after 6 months: ø -52.9 (±n/a)  
vs. -41 (±n/a); p=n/a 
Change after 12; 24; 36; 48; 60 months: n/a 
WOMAC subscale score pain (0-50)44: 
Baseline: ø 22.4 (±10.3) vs. 22.9 (±9.1); p=N.S. 
Change after 3; 6 months: n/a 
Change after 12 months: ø -16.16 (±1.16)  
vs. -16.91 (±1.21); p=N.S. 
Change after 24; 36, 48 months:n/a 
Change after 60 months: ø -15.37 (±1.47)  
vs. -16.56 (±1.19); p=N.S. 
Necessity of total joint 
replacement, n (%) 
0/1 (8) vs. 0; p=n/a n/a n/a 
                                                             
45 The Short-Form Health Survey (SF-36) version 2 is an eight-scale profile of functional health and well-being scores plus summary components of physical and mental health. 
Only the subscale scores for the physical and mental component were presented.  
46 Pain was measured on a visual analogue scale (VAS). 
47 It was not stated on which scale or scoring system the frequency and severity of pain were measured. 
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Author, year Anders 2013 [37] Sharma 2013 [39] Shive 2014 [36] (Stanish 2013 [38]) 
Safety 
Overall complications, 
n (%) 
n/a n/a 12 months follow-up (41 vs. 37 pts.): 
40 (98)48 vs. 36 (92)49; p=N.S. 
60 months follow-up (34 vs. 26 pts.): 
13 (19) vs. 18 (27)50; p=n/a 
Procedure-related 
complications, n (%) 
0/0 vs. 0 1 (7)51 vs. 0, p=n/a 12 months follow-up (41 vs. 37 pts.): 
38 (93) vs. 30 (77)52; p=n/a 
60 months follow-up (34 vs. 26 pts.): 
2 (6) vs. 2 (8)52; p=n/a 
Device-related 
complications, n (%) 
0/0 vs. - n/a vs. - 12 months follow-up (41 vs. 37 pts.): 
9 (22)53 vs. - 
60 months follow-up (34 vs. 26 pts.): 
1 (3)52 vs. - 
Re-operation rate, n (%) n/a n/a n/a 
Procedure-related 
mortality, n (%)  
n/a 0 vs. 0 0 vs. 0 
Abbreviations: cm=centimetre; CT = (non-randomised) controlled trial; MFx = microfracturing; n = number (of patients); n/a = data not available;  
N.S. = statistically not significant; pts. = patients, RCT = randomised controlled trial; vs. = versus; yrs. = years 
  
                                                             
48 5 patients experienced severe adverse events. Most frequent (mild to moderate) events: arthralgia, pain and nausea. 
49 1 patient experienced a severe adverse event. Most frequent (mild to moderate) events: arthralgia and pain. 
50 Most frequent event in both groups: pain (11% vs. 17%). 
51 Mild haemarthrosis in one patient. 
52 Kind of complications not stated. 
53 Kind of complications not clearly stated. 
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Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA 
[44] and in the Guidelines of EUnetHTA [45]. 
Table A-2: Risk of bias – study level (randomised controlled studies) 
Trial 
Adequate generation  
of randomisation 
sequence 
Adequate 
allocation 
concealment 
Blinding 
Selective outcome 
reporting unlikely 
No other aspects which 
increase the risk of bias 
Risk of bias – 
study level Patient Treating Physician 
Anders 2013 [37] Yes Yes No (not possible) No (not possible) No54 No55 High 
Shive 2014 [36] 
(Stanish 2013 [38])56 
Yes 
(Yes) 
Unclear 
(Unclear) 
No (not possible) 
(No (not possible)) 
No (not possible) 
(No (not possible)) 
Yes 
(Yes) 
No57 
(No58) 
High 
(High) 
Table A-3: Risk of bias –study level (non–randomised controlled studies) 
Study  
reference/ID 
Bias due to 
confounding 
Bias selection  
of participants 
into the study 
Bias in 
measurement  
of intervention 
Bias due to departures 
from intended 
interventions 
Bias due to 
missing data 
Bias in 
measurement  
of outcomes 
Bias in selection  
of the reported 
results Overall Bias Comments 
Sharma 2013 [39]  Serious59 Serious60 Low Moderate61 Moderate62 Serious63 Moderate64 Serious - 
 
                                                             
54 No study protocol. Incomprehensive safety reporting, unclear approach for assessing Modified ICRS. 
55 Data from interim analysis of an open-label trial. Adherence to/use of concomitant interventions not reported (i.e. to physiotherapy/rehabilitation and pain killers). 
56 Since data for 12 months follow-up were retrieved from Stanish 2013, the risk of bias of this study was also assessed. 
57 Originally, planned follow-up was 12 months and after this period the follow-up was extended to 60 months. However, there was an extra screening and enrolment  
for the extension study. Adherence to/use of concomitant interventions not reported (i.e. to physiotherapy/rehabilitation and pain killers). 
58 No adherence of possible effect of physiotherapy / rehabilitation or pain killers. 
59 Relevant baseline characteristics not comprehensively provided or controlled for. 
60 Study protocol was switched from “randomised” to “non-randomised”. Furthermore, it is unclear whether patients were recruited consecutively or not.  
61 Adherence to concomitant treatment not reported. Concomitant medication (e.g. painkillers) not reported. 
62 Values for IKDC Score were not reported (only summarised in a Figure). 
63 Subjective outcome measures, patients and trial personnel aware of intervention received. 
64 No study protocol available. 
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Applicability table 
Table A-4: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population All studies included patients with chondral defects in the knee. The patients had defects grade 3-4  
of the Outerbridge Classification (stated in one study). There was no study that exclusively included 
patients with osteochondral lesions (or with osteochondritis dissecans) in the knee. 
The inclusion criteria and the population in the studies seem to be in accordance with the intended 
patient population for the technology. 
Intervention The implantation of the scaffolds was either performed by miniarthrotomy or by an arthroscopy. 
The devices were inserted under general anaesthetics. Patients in the included studies received 
Chondro-Gide® or BST-CarGel®. In one study, it was not stated which product was used, however, 
based on the compounds, it could have been GelrinC®. 
In all studies it was stated that patients received postoperative physiotherapy or rehabilitation. 
Comparators In all studies the control group received microfracturing alone. 
To date, there are no published studies in which the single-step scaffold-assisted treatment of 
cartilage defects in combination with microfracturing has been compared with (matrix-assisted) 
autologous chondrocyte implantation/transplantation (MACI/ACI).  
Outcomes A range of clinically relevant outcome criteria was applied in the studies and have shown  
objective and/or subjective benefits from single-step scaffold-based cartilage repair combined  
with microfracturing. For the assessment of safety, procedure-, and/or device-related adverse  
events were recorded. 
However, the presented data in the studies is limited, especially due to small study samples,  
short time horizons for follow-up, and obviously different approaches to the reporting/recording  
of complications (becoming apparent in a high variability in complication rates between studies). 
Setting With one exception, the studies were carried out in Europe: Germany, Italy and the Netherlands. 
One study was a multi-centre study carried out in Canada, Spain and South Korea. Patients were 
recruited and the operations were performed at orthopaedic centres. Study centres had experience 
in the technology used, as well as in clinical research in general.  
The settings of the studies reflect the clinical setting in which the technology is intended to be used 
in an appropriate way.  
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List of ongoing randomised controlled trials 
Table A-5: List of ongoing randomised controlled trials 
Source 
Identifier/ 
Trial name Trial name Patient population Intervention Comparison Primary Outcome 
Primary 
completion date 
ClinicalTrials.gov NCT01458782 A Randomized Trial 
Comparing Autologous 
Chondrocyte Implantation 
Using Collagen Membrane 
(ACI-C) Versus (Autologous 
Matrix Induced Chondro-
genesis) AMIC for Repair of 
Cartilage Defects in the Knee 
Age between 18-60 yrs, 
symptomatic cartilage 
defect in the knee  
>2 square cm  
Autologous  
matrix induced 
chondrogenesis 
Autologous 
chondrocyte 
implantation using 
collagen membrane 
(ChondroGide) 
Perceived 
treatment efficacy 
as change from 
baseline in  
KOOS score 
October 2014 
ClinicalTrials.gov NCT01282034 Multicenter Randomized 
Controlled Trial for the 
Treatment of Knee Chondral 
and Osteochondral Lesions: 
Marrow Stimulation 
Techniques vs MaioRege 
Patients aged between  
18 and 60 years; Knee 
symptomatic chondral 
lesion of grade III/IV 
(according to Outerbridge 
Classification) or 
osteochondral lesion;  
Not re-fixable OCD lesions; 
Lesion between 2-9 cm2; 
Single lesion; 
MaioRegen 
Surgery 
Marrow stimulation 
- Drilling or 
Microfractures 
IKDC Subjective 
Knee Evaluation 
Form-2000 
July 2015 
WHO-ICTRP DRKS00005100 Evaluation der 
Rekonstruktion 
osteochondraler Läsionen 
am Talus. 
Age 18+, osteochondral 
lesions of the talus 
Autologous  
matrix induced 
chondrogenesis 
MACI/debridement 
+ drilling 
Pain n/a 
BioTissue AG 
(information  
was transmitted  
by manufacturer) 
n/a A Randomized Open-Label 
Study on Safety and Efficacy 
of chondrotissue in Micro-
fracture Treatment of Local 
Femoral Cartilage Defects 
Local femoral defect at the 
knee joint, defect size:  
1-4 cm², age 18-60 
Chondrotissue + 
microfracture 
Microfrature alone cartilage tissue 
formation after  
12 weeks as 
assessed by MRI 
December 2017 
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Literature search strategies 
Search strategy for The Cochrane Library 
Search Date: 14/01/2016 
ID Search 
#1 MeSH descriptor: [Cartilage Diseases] explode all trees 
#2 cartilage near (damage* or disorder* or defect* or lesion* or disease*) (Word variations have been searched) 
#3 MeSH descriptor: [Cartilage, Articular] explode all trees and with qualifier(s):  
[Abnormalities – AB, Injuries – IN, Pathology – PA, Physiology – PH, Physiopathology – PP] 
#4 #1 or #2 or #3  
#5 MeSH descriptor: [Knee Joint] explode all trees 
#6 Knee*  
#7 MeSH descriptor: [Ankle Joint] explode all trees 
#8 Ankle*  
#9 MeSH descriptor: [Knee Injuries] explode all trees 
#10 MeSH descriptor: [Ankle Injuries] explode all trees 
#11 MeSH descriptor: [Knee] explode all trees 
#12 MeSH descriptor: [Ankle] explode all trees 
#13 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12  
#14 #4 and #13  
#15 MeSH descriptor: [Osteochondritis Dissecans] explode all trees 
#16 osteochondritis dissecans (Word variations have been searched) 
#17 OCD:ti,ab,kw (Word variations have been searched) 
#18 osteochondr* near (damage* or disorder* or defect* or lesion* or disease*)  
(Word variations have been searched) 
#19 #15 or #16 or #17 or #18  
#20 #14 or #19  
#21 MeSH descriptor: [Chondrogenesis] explode all trees 
#22 autologous near chondrogenes* (Word variations have been searched) 
#23 Matrix-Induced Chondrogenesis (Word variations have been searched) 
#24 AMIC (Word variations have been searched) 
#25 osteochondral regeneration* (Word variations have been searched) 
#26 OCD regeneration (Word variations have been searched) 
#27 Chondro-Gide (Word variations have been searched) 
#28 Chondrotissue (Word variations have been searched) 
#29 Chondro-Tissue (Word variations have been searched) 
#30 Hyalofast (Word variations have been searched) 
#31 MaioRegen (Word variations have been searched) 
#32 “CaRes-1s” (Word variations have been searched) 
#33 #21 or #24 or #25 or #26 or #32  
#34 #4 and #33  
#35 #20 and #33  
#36 #34 or #35  
Total: 8Hits 
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Search strategy for CRD (DARE, NHS-EED, HTA) 
Search Date: 14/01/2016 
#1 (Chondrogenesis) 
#2 (autologous NEAR chondrogenes*) 
#3 (Matrix-Induced Chondrogenesis) 
#4 (AMIC) 
#5 (osteochondral regeneration*) 
#6 (OCD regeneration) 
#7 (Chondro-Gide) 
#8 (Chondrotissue) 
#9 (Chondro-Tissue) 
#10 (Hyalofast) 
#11 (MaioRegen) 
#12 (CaRes-1) 
#13 #1 OR #12 
Total:2 Hits 
 
 
Search strategy for Embase 
No. Query Results Results Date 
#37 ‘chondropathy’/exp/mj OR cartilage NEAR/4 (damage* OR disorder* OR defect* 
OR lesion* OR disease*) OR ‘articular cartilage’/mj AND (‘knee’/exp OR knee* OR 
‘ankle’/exp OR ankle* OR ‘knee injury’/exp OR ‘ankle injury’/exp) OR ‘osteochondritis 
dissecans’/exp OR ‘osteochondritis dissecans’ OR ocd OR osteochondr* NEAR/5 
(damage* OR disorder* OR defect* OR lesion* OR disease*) AND (‘chondrogenesis’/ 
exp AND (‘collagen’/exp/dm_dt,dm_th OR ‘collagen’/exp/dd_dt,dd_ad) OR 
autologous NEAR/5 chondrogenes* OR ‘matrix-induced chondrogenesis’ OR amic 
OR ‘osteochondral regeneration’ OR ‘ocd regeneration’ OR ‘chondro-gide’ OR 
chondrotissue OR ‘chondro-tissue’ OR hyalofast OR maioregen OR cares:dn OR 
cares:df) 
147 14 Jan 2016 
#36 ‘chondrogenesis’/exp AND (‘collagen’/exp/dm_dt,dm_th OR ‘collagen’/exp/ 
dd_dt,dd_ad) OR autologous NEAR/5 chondrogenes* OR ‘matrix-induced 
chondrogenesis’ OR amic OR ‘osteochondral regeneration’ OR ‘ocd regeneration’ 
OR ‘chondro-gide’ OR chondrotissue OR ‘chondro-tissue’ OR hyalofast OR 
maioregen OR cares:dn OR cares:df 
485 14 Jan 2016 
#35 cares:df 1 14 Jan 2016 
#34 cares:dn 28 14 Jan 2016 
#33 maioregen 15 14 Jan 2016 
#32 hyalofast 6 14 Jan 2016 
#31 ‘chondro-tissue’ 3 14 Jan 2016 
#30 chondrotissue 14 14 Jan 2016 
#29 ‘chondro-gide’ 54 14 Jan 2016 
#28 ‘ocd regeneration’ 1 14 Jan 2016 
#27 ‘osteochondral regeneration’ 58 14 Jan 2016 
#26 amic 308 14 Jan 2016 
#25 ‘matrix-induced chondrogenesis’ 68 14 Jan 2016 
#24 autologous NEAR/5 chondrogenes* 81 14 Jan 2016 
#23 ‘chondrogenesis’/exp AND (‘collagen’/exp/dm_dt,dm_th OR 
‘collagen’/exp/dd_dt,dd_ad) 
6 14 Jan 2016 
#22 ‘collagen’/exp/dm_dt,dm_th OR ‘collagen’/exp/dd_dt,dd_ad 2,271 14 Jan 2016 
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#21 ‘collagen’/exp/dd_dt,dd_ad 2,271 14 Jan 2016 
#20 ‘collagen’/exp/dm_dt,dm_th 1,905 14 Jan 2016 
#19 ‘chondrogenesis’/exp 7,077 14 Jan 2016 
#18 ‘chondropathy’/exp/mj OR cartilage NEAR/4 (damage* OR disorder* OR defect* 
OR lesion* OR disease*) OR ‘articular cartilage’/mj AND (‘knee’/exp OR knee* OR 
‘ankle’/exp OR ankle* OR ‘knee injury’/exp OR ‘ankle injury’/exp) OR ‘osteochondritis 
dissecans’/exp OR ‘osteochondritis dissecans’ OR ocd OR osteochondr* NEAR/5 
(damage* OR disorder* OR defect* OR lesion* OR disease*) 
26,925 14 Jan 2016 
#17 ‘osteochondritis dissecans’/exp OR ‘osteochondritis dissecans’ OR ocd OR 
osteochondr* NEAR/5 (damage* OR disorder* OR defect* OR lesion* OR disease*) 
16,594 14 Jan 2016 
#16 osteochondr* NEAR/5 (damage* OR disorder* OR defect* OR lesion* OR disease*) 5,317 14 Jan 2016 
#15 ocd 9,937 14 Jan 2016 
#14 ‘osteochondritis dissecans’ 2,654 14 Jan 2016 
#13 ‘osteochondritis dissecans’/exp 2,132 14 Jan 2016 
#12 ‘chondropathy’/exp/mj OR cartilage NEAR/4 (damage* OR disorder* OR defect* 
OR lesion* OR disease*) OR ‘articular cartilage’/mj AND (‘knee’/exp OR knee* OR 
‘ankle’/exp OR ankle* OR ‘knee injury’/exp OR ‘ankle injury’/exp) 
12,380 14 Jan 2016 
#11 ‘knee’/exp OR knee* OR ‘ankle’/exp OR ankle* OR ‘knee injury’/exp OR ‘ankle 
injury’/exp 
234,561 14 Jan 2016 
#10 ‘ankle injury’/exp  10,442 14 Jan 2016 
#9 ‘knee injury’/exp  24,314 14 Jan 2016 
#8 ankle* 74,687 14 Jan 2016 
#7 ‘ankle’/exp  23,988 14 Jan 2016 
#6 knee*  173,200 14 Jan 2016 
#5 ‘knee’/exp 51,895 14 Jan 2016 
#4 ‘chondropathy’/exp/mj OR cartilage NEAR/4 (damage* OR disorder* OR defect* 
OR lesion* OR disease*) OR ‘articular cartilage’/mj 
55,586 14 Jan 2016 
#3 ‘articular cartilage’/mj 10,491 14 Jan 2016 
#2 cartilage NEAR/4 (damage* OR disorder* OR defect* OR lesion* OR disease*) 15,301 14 Jan 2016 
#1 ‘chondropathy’/exp/mj 35,781 14 Jan 2016 
 
 
Search strategy for Medline via OVID 
Database: Ovid MEDLINE(R) <1946 to January Week 1 2016>, Ovid MEDLINE(R) In-Process & Other Non-Indexed 
Citations <January 13, 2016>, Ovid MEDLINE(R) Daily Update <January 13, 2016>, Ovid OLDMEDLINE(R)  
<1946 to 1965> 
Search Strategy: 
1 exp Cartilage Diseases/(11,591) 
2 (cartilage adj5 (damage* or disorder* or defect* or lesion* or disease*)).mp. (13,334) 
3 exp *Cartilage, Articular/ab, in, pa, ph, pp [Abnormalities, Injuries, Pathology, Physiology, Physiopathology] 
(6,639) 
4 1 or 2 or 3 (25,002) 
5 exp Knee Joint/(47,920) 
6 Knee*.mp. (125,592) 
7 exp Ankle Joint/(12,123) 
8 Ankle*.mp. (49,692) 
9 exp Knee Injuries/(16,867) 
10 exp Ankle Injuries/(8,245) 
11 5 or 6 or 7 or 8 or 9 or 10 (166,243) 
12 4 and 11 (7,529) 
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13 exp Osteochondritis Dissecans/(1,360) 
14 osteochondritis dissecans.mp. (1,948) 
15 OCD.mp. (6,692) 
16 (osteochondr* adj5 (damage* or disorder* or defect* or lesion* or disease*)).mp. (3,881) 
17 13 or 14 or 15 or 16 (11,543) 
18 12 or 17 (17,962) 
19 exp Chondrogenesis/(3346) 
20 exp *Collagen/ad, tu [Administration & Dosage, Therapeutic Use] (2,466) 
21 19 and 20 (8) 
22 (autologous adj10 chondrogenes*).mp. (64) 
23 Matrix-Induced Chondrogenesis.mp. (48) 
24 AMIC.mp. (174) 
25  osteochondral regeneration*.mp. (47) 
26 OCD regeneration.mp. (1) 
27 27 Chondro-Gide.mp. (24) 
28 28 Chondrotissue.mp. (4) 
29 29 Chondro-Tissue.mp. (1) 
30 30 Hyalofast.mp. (0) 
31 31 MaioRegen.mp. (3) 
32 32 CaRes.mp. (2,901) 
33 33 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 31 or 32 (3,179) 
34 34 18 and 33 (106) 
Search date: 13/01/2016 
 
 
Search strategy for PubMed 
(((((((Cartilage Diseases[MesH] OR cartilage damage* OR cartilage disorder* OR cartilage defect* OR cartilage lesion* 
OR cartilage disease* OR “Cartilage, Articular/abnormalities”[Mesh] OR “Cartilage, Articular/injuries”[Mesh] OR 
“Cartilage, Articular/pathology”[Mesh] OR “Cartilage, Articular/physiology”[Mesh] OR “Cartilage, Articular/ 
physiopathology”[Mesh]))) AND (Knee Joint[MesH] OR Knee* OR Ankle Joint[MesH] OR Ankle* OR Knee 
Injuries[MesH] OR Ankle Injuries[MesH]))) OR (Osteochondritis Dissecans[MesH] OR osteochondritis dissecans OR 
osteochondral damage* OR osteochondral disorder* OR osteochondral defect* OR osteochondral lesion* OR 
osteochondral disease*))) AND ((Chondrogenesis[MesH] OR “Collagen/administration and dosage”[Mesh] AND 
“Collagen/therapeutic use“[Mesh]) OR autologous chondrogenes* OR Matrix-Induced Chondrogenesis OR AMIC OR 
osteochondral regeneration* OR OCD regeneration OR Chondro-Gide OR Chondrotissue OR Chondro-Tissue OR 
Hyalofast OR MaioRegen OR CaRes) 
200 Hits 
Search date: 15/01/2016 
 
